LIMK2
TYR version of PSPA with Y as phospho-acceptor
Phospho-serine (pS) is a duplicate of phospho-tyrosine (pT) in PSPA
Position-wise Probabilities
Log-Odds: Probabilities / STY Background
Sites with acceptor types representing >8% and count ≥10 are included
S Sites Probabilities
Y Sites Probabilities
Log-Odds: S Sites / S Background
Log-Odds: Y Sites / Y Background
Sites with acceptor types representing >8% and count ≥10 are included
Motif clusters with count ≥ 10 are shown
Download
| substrate_uniprot | site | source | substrate_genes | site_seq |
|---|---|---|---|---|
| A5A3E0 | Y940 | Sugiyama | POTEF A26C1B | ALDFEQEMATVAsSSSLEKsyELPDGQVItIGNERFRCPEA |
| O14974 | T696 | Sugiyama | PPP1R12A MBS MYPT1 | EEsEsQRKARSRQARQsRRstQGVtLtDLQEAEKtIGRSRS |
| O43390 | Y136 | Sugiyama | HNRNPR HNRPR | QESTKGPDEAKIKALLERtGytLDVttGQRKYGGPPPDSVY |
| O60361 | Y136 | Sugiyama | NME2P1 | SLRFKPEELVDYKSCAHDWVyE___________________ |
| O60506 | Y133 | Sugiyama | SYNCRIP HNRPQ NSAP1 | ADSSKGPDEAKIKALLERtGytLDVttGQRKYGGPPPDSVY |
| O60841 | S182 | Sugiyama | EIF5B IF2 KIAA0741 | DGsEEDEDNsKKIKERsRINssGEsGDEsDEFLQsRKGQKK |
| P00338 | S161 | Sugiyama | LDHA PIG19 | DILTYVAWKISGFPKNRVIGsGCNLDsARFRyLMGERLGVH |
| P00338 | Y172 | Sugiyama | LDHA PIG19 | GFPKNRVIGsGCNLDsARFRyLMGERLGVHPLSCHGWVLGE |
| P00558 | Y161 | Sugiyama | PGK1 PGKA MIG10 OK/SW-cl.110 | KAEPAKIEAFRAsLSKLGDVyVNDAFGtAHRAHssMVGVNL |
| P00966 | Y359 | Sugiyama | ASS1 ASS | AKSQERVEGKVQVSVLKGQVyILGRESPLSLYNEELVSMNV |
| P04075 | S36 | Sugiyama | ALDOA ALDA | LsDIAHRIVAPGKGILAADEstGsIAKRLQsIGtENtEENR |
| P04075 | S39 | Sugiyama | ALDOA ALDA | IAHRIVAPGKGILAADEstGsIAKRLQsIGtENtEENRRFy |
| P04075 | S46 | Sugiyama | ALDOA ALDA | PGKGILAADEstGsIAKRLQsIGtENtEENRRFyRQLLLtA |
| P04406 | S241 | Sugiyama | GAPDH GAPD CDABP0047 OK/SW-cl.12 | IPELNGKLtGMAFRVPtANVsVVDLtCRLEKPAKyDDIKKV |
| P04792 | S82 | Sugiyama | HSPB1 HSP27 HSP28 | AIEsPAVAAPAYsRALsRQLssGVsEIRHtADRWRVsLDVN |
| P06733 | S27 | Sugiyama | ENO1 ENO1L1 MBPB1 MPB1 | HAREIFDsRGNPtVEVDLFtsKGLFRAAVPsGAstGIyEAL |
| P07195 | S162 | Sugiyama | LDHB | DILTYVTWKLSGLPKHRVIGsGCNLDsARFRyLMAEKLGIH |
| P07195 | S303 | Sugiyama | LDHB | GIENEVFLSLPCILNARGLtsVINQKLKDDEVAQLKKsADt |
| P07205 | Y161 | Sugiyama | PGK2 PGKB | KAEPDKIEAFRAsLSKLGDVyVNDAFGtAHRAHSSMVGVNL |
| P07237 | Y94 | Sugiyama | P4HB ERBA2L PDI PDIA1 PO4DB | GSEIRLAKVDAtEEsDLAQQyGVRGyPtIKFFRNGDTASPK |
| P07437 | Y50 | Sugiyama | TUBB TUBB5 OK/SW-cl.56 | IDPTGtyHGDsDLQLDRIsVyyNEAtGGKyVPRAILVDLEP |
| P07737 | S30 | Sugiyama | PFN1 | NLMADGTCQDAAIVGYKDsPsVWAAVPGKtFVNITPAEVGV |
| P07814 | S335 | Sugiyama | EPRS1 EPRS GLNS PARS QARS QPRS PIG32 | PIEKNLQMWEEMKKGsQFGQsCCLRAKIDMSSNNGCMRDPt |
| P07814 | Y1505 | Sugiyama | EPRS1 EPRS GLNS PARS QARS QPRS PIG32 | PLCELQPGAKCVCGKNPAKyytLFGRsy_____________ |
| P07864 | S161 | Sugiyama | LDHC LDH3 LDHX | DILTYIVWKISGLPVTRVIGsGCNLDsARFRYLIGEKLGVH |
| P07900 | Y492 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | DEMVsLKDYCTRMKENQKHIyyItGETKDQVANsAFVERLR |
| P07900 | Y493 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | EMVsLKDYCTRMKENQKHIyyItGETKDQVANsAFVERLRK |
| P08238 | S468 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | RRRLsELLRyHtsQsGDEMtsLsEyVsRMKEtQKsIyyItG |
| P08238 | S497 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | KEtQKsIyyItGEsKEQVANsAFVERVRKRGFEVVyMtEPI |
| P08238 | Y484 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | DEMtsLsEyVsRMKEtQKsIyyItGEsKEQVANsAFVERVR |
| P08238 | Y485 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | EMtsLsEyVsRMKEtQKsIyyItGEsKEQVANsAFVERVRK |
| P08238 | Y619 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | TANMERIMKAQALRDNstMGyMMAKKHLEINPDHPIVEtLR |
| P09651 | S360 | Sugiyama | HNRNPA1 HNRPA1 | PyGGGGQyFAKPRNQGGyGGssssssyGsGRRF________ |
| P10809 | S488 | Sugiyama | HSPD1 HSP60 | IKRTLKIPAMtIAKNAGVEGsLIVEKIMQSSsEVGYDAMAG |
| P11142 | Y41 | Sugiyama | HSPA8 HSC70 HSP73 HSPA10 | FQHGKVEIIANDQGNRttPsyVAFtDtERLIGDAAKNQVAM |
| P11940 | Y194 | Sugiyama | PABPC1 PAB1 PABP PABP1 PABPC2 | KSRKEREAELGARAKEFtNVyIKNFGEDMDDERLKDLFGKF |
| P13639 | S38 | Sugiyama | EEF2 EF2 | NIRNMsVIAHVDHGKStLtDsLVCKAGIIAsARAGEtRFtD |
| P13639 | S593 | Sugiyama | EEF2 EF2 | SDPVVsyREtVsEEsNVLCLsKsPNKHNRLyMKARPFPDGL |
| P13639 | Y671 | Sugiyama | EEF2 EF2 | CFGPDGTGPNILTDITKGVQyLNEIKDSVVAGFQWATKEGA |
| P14625 | Y727 | Sugiyama | HSP90B1 GRP94 HSPC4 TRA1 | DKTVLDLAVVLFETATLRsGyLLPDTKAYGDRIERMLRLsL |
| P17066 | Y43 | Sugiyama | HSPA6 HSP70B' | FQQGRVEILANDQGNRTtPsyVAFtDtERLVGDAAKsQAAL |
| P18583 | S2011 | Sugiyama | SON C21orf50 DBP5 KIAA1019 NREBP HSPC310 HSPC312 | RSRTPSRRRRSRSVVRRRsFsIsPVRLRRSRTPLRRRFsRs |
| P18621 | S5 | Sugiyama | RPL17 | ________________MVRysLDPENPtKsCKSRGSNLRVH |
| P18621 | Y4 | Sugiyama | RPL17 | _________________MVRysLDPENPtKsCKSRGSNLRV |
| P19338 | Y462 | Sugiyama | NCL | AEKTFEEKQGtEIDGRsIsLyytGEKGQNQDYRGGKNSTWs |
| P20042 | Y176 | Sugiyama | EIF2S2 EIF2B | GIsFsNQtGPAWAGSERDytyEELLNRVFNIMREKNPDMVA |
| P21333 | Y2379 | Sugiyama | FLNA FLN FLN1 | GAKGAIDAKVHsPsGALEECyVtEIDQDKYAVRFIPRENGV |
| P22392 | Y151 | Sugiyama | NME2 NM23B | SLWFKPEELVDyKSCAHDWVyE___________________ |
| P23528 | S3 | GPS6|SIGNOR|ELM|iPTMNet|EPSD|PSP | CFL1 CFL | __________________MAsGVAVsDGVIKVFNDMKVRKs |
| P25398 | Y127 | Sugiyama | RPS12 | sCVVVKDYGKESQAKDVIEEyFKCKK_______________ |
| P26373 | S77 | Sugiyama | RPL13 BBC1 OK/SW-cl.46 | PIVRCPTVRYHTKVRAGRGFsLEELRVAGIHKKVARTIGIs |
| P27348 | Y48 | Sugiyama | YWHAQ | AVtEQGAELsNEERNLLsVAyKNVVGGRRSAWRVIsSIEQK |
| P27797 | S52 | Sugiyama | CALR CRTC | GWtsRWIEsKHKSDFGKFVLssGKFyGDEEKDKGLQTSQDA |
| P30101 | Y100 | Sugiyama | PDIA3 ERP57 ERP60 GRP58 | LAKVDCTANTNTCNKyGVsGyPtLKIFRDGEEAGAyDGPRt |
| P31946 | Y50 | Sugiyama | YWHAB | AVtEQGHELsNEERNLLsVAyKNVVGARRSsWRVIsSIEQK |
| P31947 | Y48 | Sugiyama | SFN HME1 | GAVEKGEELsCEERNLLsVAyKNVVGGQRAAWRVLSsIEQK |
| P32969 | S182 | Sugiyama | RPL9 OK/SW-cl.103; RPL9P7; RPL9P8; RPL9P9 | QQATTVKNKDIRKFLDGIyVsEKGtVQQADE__________ |
| P32969 | Y180 | Sugiyama | RPL9 OK/SW-cl.103; RPL9P7; RPL9P8; RPL9P9 | LIQQATTVKNKDIRKFLDGIyVsEKGtVQQADE________ |
| P34931 | Y43 | Sugiyama | HSPA1L | FQHGKVEIIANDQGNRttPsyVAFtDtERLIGDAAKNQVAM |
| P38646 | S200 | Sugiyama | HSPA9 GRP75 HSPA9B mt-HSP70 | NyLGHtAKNAVItVPAyFNDsQRQAtKDAGQIsGLNVLRVI |
| P39019 | Y54 | Sugiyama | RPS19 | VDtVKLAKHKELAPyDENWFytRAAstARHLYLRGGAGVGs |
| P39023 | S13 | Sugiyama | RPL3 OK/SW-cl.32 | ________MSHRKFSAPRHGsLGFLPRKRSSRHRGKVKSFP |
| P40227 | S246 | Sugiyama | CCT6A CCT6 CCTZ | EDAyILTCNVSLEYEKTEVNsGFFyKSAEEREKLVKAERKF |
| P43243 | S188 | Sugiyama | MATR3 KIAA0723 | EPPyRVPRDDWEEKRHFRRDsFDDRGPsLNPVLDyDHGsRs |
| P46108 | S41 | Sugiyama | CRK | QEAVALLQGQRHGVFLVRDsstsPGDyVLSVSENSRVSHYI |
| P46776 | S68 | Sugiyama | RPL27A | yHPGyFGKVGMKHYHLKRNQsFCPtVNLDKLWtLVsEQtRV |
| P46777 | S176 | Sugiyama | RPL5 MSTP030 | GNKVFGALKGAVDGGLsIPHstKRFPGyDsEsKEFNAEVHR |
| P48741 | Y43 | Sugiyama | HSPA7 HSP70B | FQQGRVEILANDQGNRTtPsyVAFtDtERLVGDAAKsQAAL |
| P49207 | Y32 | Sugiyama | RPL34 | sYNtASNKTRLSRTPGNRIVyLytKKVGKAPKSACGVCPGR |
| P49207 | Y34 | Sugiyama | RPL34 | NtASNKTRLSRTPGNRIVyLytKKVGKAPKSACGVCPGRLR |
| P49840 | Y279 | Sugiyama | GSK3A | LKLCDFGSAKQLVRGEPNVsyICsRYYRAPELIFGATDYTS |
| P49841 | Y216 | Sugiyama | GSK3B | LKLCDFGSAKQLVRGEPNVsyICsRYYRAPELIFGATDYTS |
| P50395 | S396 | Sugiyama | GDI2 RABGDIB | IEQKFVsISDLLVPKDLGtEsQIFIsRTyDAttHFEttCDD |
| P53671 | S100 | Sugiyama | LIMK2 | TGPFMVAGEFKYHPECFACMsCKVIIEDGDAYALVQHATLY |
| P53671 | S22 | Sugiyama | LIMK2 | SALAGEDVWRCPGCGDHIAPsQIWyRTVNETWHGsCFRCSE |
| P53671 | S36 | Sugiyama | LIMK2 | GDHIAPsQIWyRTVNETWHGsCFRCSECQDSLTNWyyEKDG |
| P53671 | T278 | Sugiyama | LIMK2 | QNAGHPHALSTLDTKENLEGtLRRRsLRRsNsIsKsPGPss |
| P53671 | Y26 | Sugiyama | LIMK2 | GEDVWRCPGCGDHIAPsQIWyRTVNETWHGsCFRCSECQDS |
| P53671 | Y51 | Sugiyama | LIMK2 | ETWHGsCFRCSECQDSLTNWyyEKDGKLYCPKDYWGKFGEF |
| P53671 | Y52 | Sugiyama | LIMK2 | TWHGsCFRCSECQDSLTNWyyEKDGKLYCPKDYWGKFGEFC |
| P54652 | Y42 | Sugiyama | HSPA2 | FQHGKVEIIANDQGNRttPsyVAFtDtERLIGDAAKNQVAM |
| P60709 | S52 | Sugiyama | ACTB | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKYPIE |
| P60709 | Y240 | Sugiyama | ACTB | ALDFEQEMAtAAssssLEKsyELPDGQVItIGNERFRCPEA |
| P60981 | S3 | EPSD|PSP | DSTN ACTDP DSN | __________________MAsGVQVADEVCRIFYDMKVRKC |
| P61313 | Y6 | Sugiyama | RPL15 EC45 TCBAP0781 | _______________MGAYKyIQELWRKKQSDVMRFLLRVR |
| P61981 | Y49 | Sugiyama | YWHAG | NVtELNEPLsNEERNLLsVAyKNVVGARRSsWRVIsSIEQK |
| P62249 | S9 | Sugiyama | RPS16 | ____________MPsKGPLQsVQVFGRKKTATAVAHCKRGN |
| P62258 | Y49 | Sugiyama | YWHAE | KVAGMDVELTVEERNLLsVAyKNVIGARRASWRIIssIEQK |
| P62269 | Y95 | Sugiyama | RPS18 D6S218E | RQYKIPDWFLNRQKDVKDGKysQVLANGLDNKLREDLERLK |
| P62273 | Y7 | Sugiyama | RPS29 | ______________MGHQQLyWsHPRKFGQGSRSCRVCSNR |
| P62736 | S54 | Sugiyama | ACTA2 ACTSA ACTVS GIG46 | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIE |
| P62736 | Y242 | Sugiyama | ACTA2 ACTSA ACTVS GIG46 | ALDFENEMAtAAssssLEKsyELPDGQVItIGNERFRCPET |
| P62750 | Y144 | Sugiyama | RPL23A | VNtLIRPDGEKKAYVRLAPDyDALDVANKIGII________ |
| P62826 | Y146 | Sugiyama | RAN ARA24 OK/SW-cl.81 | IKDRKVKAKsIVFHRKKNLQyyDIsAKSNyNFEKPFLWLAR |
| P62979 | Y148 | Sugiyama | RPS27A UBA80 UBCEP1 | AGVFMAsHFDRHyCGKCCLtyCFNKPEDK____________ |
| P63104 | Y48 | Sugiyama | YWHAZ | sVtEQGAELsNEERNLLsVAyKNVVGARRssWRVVssIEQK |
| P63220 | Y53 | Sugiyama | RPS21 | QMNVAEVDKVTGRFNGQFKtyAICGAIRRMGEsDDsILRLA |
| P63261 | S52 | Sugiyama | ACTG1 ACTG | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKYPIE |
| P63261 | Y240 | Sugiyama | ACTG1 ACTG | ALDFEQEMAtAAssssLEKsyELPDGQVItIGNERFRCPEA |
| P63267 | S53 | Sugiyama | ACTG2 ACTA3 ACTL3 ACTSG | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIE |
| P63267 | Y241 | Sugiyama | ACTG2 ACTA3 ACTL3 ACTSG | ALDFENEMAtAAssssLEKsyELPDGQVItIGNERFRCPET |
| P67809 | Y196 | Sugiyama | YBX1 NSEP1 YB1 | sAPEGQAQQRRPyRRRRFPPyyMRRPYGRRPQysNPPVQGE |
| P68032 | S54 | Sugiyama | ACTC1 ACTC | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIE |
| P68032 | Y242 | Sugiyama | ACTC1 ACTC | ALDFENEMAtAAssssLEKsyELPDGQVItIGNERFRCPET |
| P68104 | Y29 | Sugiyama | EEF1A1 EEF1A EF1A LENG7 | NIVVIGHVDsGKstttGHLIyKCGGIDKRTIEKFEKEAAEM |
| P68133 | S54 | Sugiyama | ACTA1 ACTA | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIE |
| P68133 | Y242 | Sugiyama | ACTA1 ACTA | ALDFENEMAtAAssssLEKsyELPDGQVItIGNERFRCPET |
| Q00839 | Y257 | Sugiyama | HNRNPU C1orf199 HNRPU SAFA U21.1 | QKGGDKKRGVKRPREDHGRGyFEyIEENKysRAKsPQPPVE |
| Q00839 | Y260 | Sugiyama | HNRNPU C1orf199 HNRPU SAFA U21.1 | GDKKRGVKRPREDHGRGyFEyIEENKysRAKsPQPPVEEED |
| Q04917 | Y49 | Sugiyama | YWHAH YWHA1 | AVtELNEPLsNEDRNLLsVAyKNVVGARRSsWRVIsSIEQK |
| Q05639 | Y29 | Sugiyama | EEF1A2 EEF1AL STN | NIVVIGHVDsGKstttGHLIyKCGGIDKRTIEKFEKEAAEM |
| Q06830 | S32 | Sugiyama | PRDX1 PAGA PAGB TDPX2 | APNFKAtAVMPDGQFKDIsLsDyKGKYVVFFFYPLDFTFVC |
| Q06830 | Y116 | Sugiyama | PRDX1 PAGA PAGB TDPX2 | GLGPMNIPLVSDPKRtIAQDyGVLKADEGIsFRGLFIIDDK |
| Q13263 | Y133 | Sugiyama | TRIM28 KAP1 RNF96 TIF1B | TVVDCPVCKQQCFSKDIVENyFMRDsGsKAATDAQDANQCC |
| Q13283 | Y125 | Sugiyama | G3BP1 G3BP | LRRFMQtFVLAPEGsVANKFyVHNDIFRyQDEVFGGFVtEP |
| Q13310 | Y194 | Sugiyama | PABPC4 APP1 PABP4 | KSRKEREAELGAKAKEFtNVyIKNFGEEVDDEsLKELFsQF |
| Q13765 | Y120 | Sugiyama | NACA HSD48 | KNILFVITKPDVYKSPAsDtyIVFGEAKIEDLsQQAQLAAA |
| Q15080 | S67 | Sugiyama | NCF4 SH3PXD4 | TKGGSKYLIYRRYRQFHALQsKLEERFGPDSKSSALACTLP |
| Q15185 | S72 | Sugiyama | PTGES3 P23 TEBP | EIDLFHCIDPNDsKHKRtDRsILCCLRKGEsGQsWPRLTKE |
| Q562R1 | Y241 | Sugiyama | ACTBL2 | ALDFEQEMVRAAAssSPERsyELPDGQVItIGNERFRCPEA |
| Q58FF7 | S370 | Sugiyama | HSP90AB3P HSP90BC | KETQKSTYYITGESKEQVANsAFVERVRKQGFEVVYMTEPI |
| Q58FF7 | Y492 | Sugiyama | HSP90AB3P HSP90BC | TANMEQIMKAQALRDNstMGyMMAKKHLEINPDHPIMETLR |
| Q58FF8 | Y260 | Sugiyama | HSP90AB2P HSP90BB | VRYFSVEEYVSRMKEIQKsIyyItGEsKEQVANSAFVEQVW |
| Q58FF8 | Y261 | Sugiyama | HSP90AB2P HSP90BB | RYFSVEEYVSRMKEIQKsIyyItGEsKEQVANSAFVEQVWK |
| Q58FG0 | Y177 | Sugiyama | HSP90AA5P HSP90AE | GQLEELKDSRRVMKANQKHIyyItGETKDQVANSAFVECLQ |
| Q58FG0 | Y178 | Sugiyama | HSP90AA5P HSP90AE | QLEELKDSRRVMKANQKHIyyItGETKDQVANSAFVECLQK |
| Q5VTE0 | Y29 | Sugiyama | EEF1A1P5 EEF1AL3 | NIVVIGHVDsGKstttGHLIyKCGGIDKRTIEKFEKEAAEM |
| Q6S8J3 | Y940 | Sugiyama | POTEE A26C1A POTE2 | ALDFEQEMAtAAssssLEKsyELPDGQVItIGNERFRCPEA |
| Q6ZMR3 | S161 | Sugiyama | LDHAL6A LDHL2 | DILTYVAWKLSGFPKNRVIGsGCNLDsARFRYFIGQRLGIH |
| Q92526 | S246 | Sugiyama | CCT6B | EDAFILICNVSLEYEKTEVNsGFFyKTAEEKEKLVKAERKF |
| Q9BYX7 | Y240 | Sugiyama | POTEKP ACTBL3 FKSG30 | ALDSEQEMAMAASSSSVEKsyELPDGQVItIGNERFRCPEA |
| Q9Y3D8 | Y31 | Sugiyama | AK6 CINAP AD-004 CGI-137 | TPGVGKTTLGKELASKSGLKyINVGDLAREEQLYDGYDEEY |
Site Promiscuity
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Interleukin-1 family signaling | R-HSA-446652 | 0.000002 | 5.745 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 0.000040 | 4.400 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 0.000040 | 4.400 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 0.000051 | 4.290 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 0.000080 | 4.098 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 0.000120 | 3.921 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 0.000191 | 3.719 | 0 | 0 |
| Immune System | R-HSA-168256 | 0.000271 | 3.567 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 0.000261 | 3.584 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 0.000357 | 3.447 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 0.000620 | 3.208 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 0.000897 | 3.047 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 0.001123 | 2.950 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 0.001130 | 2.947 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 0.001051 | 2.978 | 1 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 0.001487 | 2.828 | 0 | 0 |
| RUNX2 regulates genes involved in differentiation of myeloid cells | R-HSA-8941333 | 0.001804 | 2.744 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 0.002294 | 2.639 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 0.002294 | 2.639 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 0.002033 | 2.692 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 0.002290 | 2.640 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 0.002362 | 2.627 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 0.002129 | 2.672 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 0.002660 | 2.575 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 0.002736 | 2.563 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 0.003415 | 2.467 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 0.006079 | 2.216 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 0.005900 | 2.229 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 0.005900 | 2.229 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 0.005900 | 2.229 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | R-HSA-8939246 | 0.005864 | 2.232 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 0.005816 | 2.235 | 1 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 0.005793 | 2.237 | 0 | 0 |
| Drug resistance of ALK mutants | R-HSA-9700649 | 0.010195 | 1.992 | 0 | 0 |
| brigatinib-resistant ALK mutants | R-HSA-9717319 | 0.010195 | 1.992 | 0 | 0 |
| alectinib-resistant ALK mutants | R-HSA-9717316 | 0.010195 | 1.992 | 0 | 0 |
| NVP-TAE684-resistant ALK mutants | R-HSA-9717301 | 0.010195 | 1.992 | 0 | 0 |
| lorlatinib-resistant ALK mutants | R-HSA-9717329 | 0.010195 | 1.992 | 0 | 0 |
| ceritinib-resistant ALK mutants | R-HSA-9717323 | 0.010195 | 1.992 | 0 | 0 |
| crizotinib-resistant ALK mutants | R-HSA-9717326 | 0.010195 | 1.992 | 0 | 0 |
| ASP-3026-resistant ALK mutants | R-HSA-9717264 | 0.010195 | 1.992 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 0.008932 | 2.049 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 0.006274 | 2.202 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 0.010152 | 1.993 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 0.007982 | 2.098 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 0.008347 | 2.078 | 0 | 0 |
| RHOBTB3 ATPase cycle | R-HSA-9706019 | 0.009310 | 2.031 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 0.006415 | 2.193 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 0.007982 | 2.098 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 0.009530 | 2.021 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 0.007653 | 2.116 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 0.009595 | 2.018 | 1 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 0.006932 | 2.159 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 0.008847 | 2.053 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 0.007131 | 2.147 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 0.009638 | 2.016 | 0 | 0 |
| ChREBP activates metabolic gene expression | R-HSA-163765 | 0.009310 | 2.031 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 0.009601 | 2.018 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 0.008942 | 2.049 | 0 | 0 |
| Phosphorylation and nuclear translocation of the CRY:PER:kinase complex | R-HSA-9931530 | 0.011999 | 1.921 | 0 | 0 |
| p75NTR recruits signalling complexes | R-HSA-209543 | 0.011999 | 1.921 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 0.012156 | 1.915 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 0.014931 | 1.826 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 0.014794 | 1.830 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 0.016586 | 1.780 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 0.016586 | 1.780 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 0.016586 | 1.780 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 0.016801 | 1.775 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 0.016801 | 1.775 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 0.016838 | 1.774 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 0.017054 | 1.768 | 0 | 0 |
| Drug-mediated inhibition of MET activation | R-HSA-9734091 | 0.020286 | 1.693 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 0.020798 | 1.682 | 0 | 0 |
| Nef mediated downregulation of CD28 cell surface expression | R-HSA-164939 | 0.030275 | 1.519 | 0 | 0 |
| Loss of Function of SMAD4 in Cancer | R-HSA-3304347 | 0.030275 | 1.519 | 0 | 0 |
| Defective POMGNT1 causes MDDGA3, MDDGB3 and MDDGC3 | R-HSA-5083628 | 0.030275 | 1.519 | 0 | 0 |
| SMAD4 MH2 Domain Mutants in Cancer | R-HSA-3311021 | 0.030275 | 1.519 | 0 | 0 |
| MyD88 deficiency (TLR5) | R-HSA-5602680 | 0.030275 | 1.519 | 0 | 0 |
| SMAD2/3 MH2 Domain Mutants in Cancer | R-HSA-3315487 | 0.030275 | 1.519 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 0.027595 | 1.559 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 0.027595 | 1.559 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 0.023311 | 1.632 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 0.029651 | 1.528 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 0.023668 | 1.626 | 0 | 0 |
| Inhibition of membrane repair | R-HSA-9635644 | 0.030275 | 1.519 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 0.021854 | 1.660 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 0.026520 | 1.576 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 0.026520 | 1.576 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 0.026520 | 1.576 | 0 | 0 |
| Other interleukin signaling | R-HSA-449836 | 0.025601 | 1.592 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 0.031552 | 1.501 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 0.029562 | 1.529 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 0.029831 | 1.525 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 0.025010 | 1.602 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 0.027595 | 1.559 | 0 | 0 |
| Polo-like kinase mediated events | R-HSA-156711 | 0.023668 | 1.626 | 0 | 0 |
| FOXO-mediated transcription of cell death genes | R-HSA-9614657 | 0.023668 | 1.626 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 0.027654 | 1.558 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 0.024013 | 1.620 | 0 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 0.021798 | 1.662 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 0.027654 | 1.558 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 0.030622 | 1.514 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 0.029788 | 1.526 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 0.023248 | 1.634 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 0.022957 | 1.639 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 0.031765 | 1.498 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 0.031765 | 1.498 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 0.040162 | 1.396 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 0.040162 | 1.396 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 0.040162 | 1.396 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 0.040162 | 1.396 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 0.040162 | 1.396 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 0.040162 | 1.396 | 0 | 0 |
| Defective POMT1 causes MDDGA1, MDDGB1 and MDDGC1 | R-HSA-5083633 | 0.040162 | 1.396 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 0.040162 | 1.396 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 0.040162 | 1.396 | 0 | 0 |
| Defective POMT2 causes MDDGA2, MDDGB2 and MDDGC2 | R-HSA-5083629 | 0.040162 | 1.396 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 0.040162 | 1.396 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 0.040162 | 1.396 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 0.040162 | 1.396 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 0.049950 | 1.301 | 0 | 0 |
| Axonal growth stimulation | R-HSA-209563 | 0.049950 | 1.301 | 0 | 0 |
| IRAK4 deficiency (TLR5) | R-HSA-5603037 | 0.049950 | 1.301 | 0 | 0 |
| Invadopodia formation | R-HSA-8941237 | 0.049950 | 1.301 | 0 | 0 |
| MET activates PTPN11 | R-HSA-8865999 | 0.049950 | 1.301 | 0 | 0 |
| RUNX3 regulates BCL2L11 (BIM) transcription | R-HSA-8952158 | 0.059638 | 1.224 | 0 | 0 |
| Noncanonical activation of NOTCH3 | R-HSA-9017802 | 0.078721 | 1.104 | 0 | 0 |
| Defective CSF2RA causes SMDP4 | R-HSA-5688890 | 0.078721 | 1.104 | 0 | 0 |
| Defective CSF2RB causes SMDP5 | R-HSA-5688849 | 0.078721 | 1.104 | 0 | 0 |
| MET activates PI3K/AKT signaling | R-HSA-8851907 | 0.097419 | 1.011 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 0.097419 | 1.011 | 0 | 0 |
| Recycling of eIF2:GDP | R-HSA-72731 | 0.097419 | 1.011 | 0 | 0 |
| DAG1 core M1 glycosylations | R-HSA-8932506 | 0.097419 | 1.011 | 0 | 0 |
| DAG1 core M2 glycosylations | R-HSA-8932504 | 0.106626 | 0.972 | 0 | 0 |
| MET receptor recycling | R-HSA-8875656 | 0.106626 | 0.972 | 0 | 0 |
| Interleukin-21 signaling | R-HSA-9020958 | 0.115740 | 0.937 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 0.115740 | 0.937 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 0.124761 | 0.904 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 0.124761 | 0.904 | 0 | 0 |
| DAG1 core M3 glycosylations | R-HSA-8932505 | 0.133691 | 0.874 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 0.036165 | 1.442 | 0 | 0 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 0.142531 | 0.846 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 0.043174 | 1.365 | 0 | 0 |
| MET activates RAS signaling | R-HSA-8851805 | 0.151280 | 0.820 | 0 | 0 |
| Defective EXT2 causes exostoses 2 | R-HSA-3656237 | 0.151280 | 0.820 | 0 | 0 |
| Defective EXT1 causes exostoses 1, TRPS2 and CHDS | R-HSA-3656253 | 0.151280 | 0.820 | 0 | 0 |
| Cristae formation | R-HSA-8949613 | 0.045613 | 1.341 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 0.185400 | 0.732 | 0 | 0 |
| Defective B3GALT6 causes EDSP2 and SEMDJL1 | R-HSA-4420332 | 0.193715 | 0.713 | 0 | 0 |
| Defective B4GALT7 causes EDS, progeroid type | R-HSA-3560783 | 0.193715 | 0.713 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 0.078424 | 1.106 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 0.106541 | 0.972 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 0.126556 | 0.898 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 0.129974 | 0.886 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 0.062639 | 1.203 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 0.159941 | 0.796 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 0.177000 | 0.752 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 0.075466 | 1.122 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 0.140354 | 0.853 | 0 | 0 |
| Regulation of IFNA/IFNB signaling | R-HSA-912694 | 0.033937 | 1.469 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 0.193715 | 0.713 | 0 | 0 |
| MDK and PTN in ALK signaling | R-HSA-9851151 | 0.059638 | 1.224 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 0.058773 | 1.231 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 0.048103 | 1.318 | 0 | 0 |
| IRF3 mediated activation of type 1 IFN | R-HSA-1606341 | 0.069228 | 1.160 | 0 | 0 |
| Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | R-HSA-9828211 | 0.106626 | 0.972 | 0 | 0 |
| Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | R-HSA-9824878 | 0.142531 | 0.846 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 0.054491 | 1.264 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 0.093732 | 1.028 | 0 | 0 |
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | R-HSA-3134963 | 0.069228 | 1.160 | 0 | 0 |
| MET Receptor Activation | R-HSA-6806942 | 0.088118 | 1.055 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 0.177000 | 0.752 | 0 | 0 |
| TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling | R-HSA-975110 | 0.193715 | 0.713 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 0.113113 | 0.946 | 0 | 0 |
| Complex IV assembly | R-HSA-9864848 | 0.123160 | 0.910 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 0.036985 | 1.432 | 0 | 0 |
| STAT6-mediated induction of chemokines | R-HSA-3249367 | 0.049950 | 1.301 | 0 | 0 |
| MET activates STAT3 | R-HSA-8875791 | 0.049950 | 1.301 | 0 | 0 |
| RUNX3 regulates CDKN1A transcription | R-HSA-8941855 | 0.078721 | 1.104 | 0 | 0 |
| Loss of Function of SMAD2/3 in Cancer | R-HSA-3304349 | 0.078721 | 1.104 | 0 | 0 |
| Fructose biosynthesis | R-HSA-5652227 | 0.106626 | 0.972 | 0 | 0 |
| p75NTR regulates axonogenesis | R-HSA-193697 | 0.115740 | 0.937 | 0 | 0 |
| Ion influx/efflux at host-pathogen interface | R-HSA-6803544 | 0.124761 | 0.904 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 0.151280 | 0.820 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 0.048103 | 1.318 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 0.055858 | 1.253 | 0 | 0 |
| Antigen processing: Ub, ATP-independent proteasomal degradation | R-HSA-9912633 | 0.193715 | 0.713 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 0.106541 | 0.972 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 0.039574 | 1.403 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 0.092169 | 1.035 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 0.066819 | 1.175 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 0.084446 | 1.073 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 0.193715 | 0.713 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 0.147299 | 0.832 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 0.039863 | 1.399 | 0 | 0 |
| Regulation of innate immune responses to cytosolic DNA | R-HSA-3134975 | 0.193715 | 0.713 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 0.100311 | 0.999 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 0.194448 | 0.711 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 0.147299 | 0.832 | 0 | 0 |
| TICAM1-dependent activation of IRF3/IRF7 | R-HSA-9013973 | 0.142531 | 0.846 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 0.193715 | 0.713 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 0.118268 | 0.927 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 0.190755 | 0.720 | 0 | 0 |
| Pyrophosphate hydrolysis | R-HSA-71737 | 0.069228 | 1.160 | 0 | 0 |
| Axonal growth inhibition (RHOA activation) | R-HSA-193634 | 0.106626 | 0.972 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 0.115740 | 0.937 | 0 | 0 |
| Regulation of ornithine decarboxylase (ODC) | R-HSA-350562 | 0.058534 | 1.233 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 0.069663 | 1.157 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 0.069663 | 1.157 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 0.090604 | 1.043 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 0.090604 | 1.043 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 0.109814 | 0.959 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 0.126556 | 0.898 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 0.129974 | 0.886 | 0 | 0 |
| Signaling by Activin | R-HSA-1502540 | 0.177000 | 0.752 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 0.145137 | 0.838 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 0.036717 | 1.435 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex in Cancer | R-HSA-3304351 | 0.088118 | 1.055 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 0.043174 | 1.365 | 0 | 0 |
| Diseases associated with surfactant metabolism | R-HSA-5687613 | 0.151280 | 0.820 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 0.075466 | 1.122 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 0.048885 | 1.311 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 0.048885 | 1.311 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 0.052235 | 1.282 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 0.052235 | 1.282 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 0.040553 | 1.392 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 0.043575 | 1.361 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 0.067727 | 1.169 | 0 | 0 |
| Co-inhibition by BTLA | R-HSA-9927353 | 0.069228 | 1.160 | 0 | 0 |
| WNT mediated activation of DVL | R-HSA-201688 | 0.115740 | 0.937 | 0 | 0 |
| Regulation of IFNG signaling | R-HSA-877312 | 0.151280 | 0.820 | 0 | 0 |
| Advanced glycosylation endproduct receptor signaling | R-HSA-879415 | 0.151280 | 0.820 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 0.045613 | 1.341 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 0.177000 | 0.752 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 0.072545 | 1.139 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 0.072545 | 1.139 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 0.075466 | 1.122 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 0.075466 | 1.122 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 0.126556 | 0.898 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 0.133414 | 0.875 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 0.088206 | 1.055 | 1 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 0.158025 | 0.801 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 0.190755 | 0.720 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 0.108191 | 0.966 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 0.060971 | 1.215 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 0.063003 | 1.201 | 0 | 0 |
| Nef and signal transduction | R-HSA-164944 | 0.088118 | 1.055 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 0.036165 | 1.442 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 0.064015 | 1.194 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 0.066819 | 1.175 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 0.066819 | 1.175 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 0.069663 | 1.157 | 0 | 0 |
| Synthesis of PG | R-HSA-1483148 | 0.193715 | 0.713 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 0.090604 | 1.043 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 0.090604 | 1.043 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 0.119787 | 0.922 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 0.126556 | 0.898 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 0.069541 | 1.158 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 0.032745 | 1.485 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 0.036436 | 1.438 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 0.036436 | 1.438 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 0.158025 | 0.801 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 0.155111 | 0.809 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 0.037656 | 1.424 | 0 | 0 |
| Regulation of NF-kappa B signaling | R-HSA-9758274 | 0.185400 | 0.732 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 0.080505 | 1.094 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 0.037656 | 1.424 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 0.033100 | 1.480 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 0.154457 | 0.811 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 0.037656 | 1.424 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 0.057497 | 1.240 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 0.190755 | 0.720 | 0 | 0 |
| Cellular response to mitochondrial stress | R-HSA-9840373 | 0.115740 | 0.937 | 0 | 0 |
| Galactose catabolism | R-HSA-70370 | 0.193715 | 0.713 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 0.084446 | 1.073 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 0.087509 | 1.058 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 0.087509 | 1.058 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 0.129974 | 0.886 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 0.132312 | 0.878 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 0.087509 | 1.058 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 0.136874 | 0.864 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 0.167646 | 0.776 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 0.035793 | 1.446 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 0.194448 | 0.711 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 0.194448 | 0.711 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 0.115740 | 0.937 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 0.133691 | 0.874 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 0.081418 | 1.089 | 0 | 0 |
| Cross-presentation of soluble exogenous antigens (endosomes) | R-HSA-1236978 | 0.081418 | 1.089 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 0.096890 | 1.014 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 0.100078 | 1.000 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 0.103296 | 0.986 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 0.140354 | 0.853 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 0.053379 | 1.273 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 0.140354 | 0.853 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 0.100311 | 0.999 | 0 | 0 |
| PI5P Regulates TP53 Acetylation | R-HSA-6811555 | 0.159941 | 0.796 | 0 | 0 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | R-HSA-5684264 | 0.168514 | 0.773 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 0.168514 | 0.773 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 0.072545 | 1.139 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 0.103296 | 0.986 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 0.140354 | 0.853 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 0.140354 | 0.853 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 0.126352 | 0.898 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 0.168820 | 0.773 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 0.104487 | 0.981 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 0.115221 | 0.938 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 0.066854 | 1.175 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 0.084446 | 1.073 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 0.087509 | 1.058 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 0.103296 | 0.986 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 0.054536 | 1.263 | 0 | 0 |
| S Phase | R-HSA-69242 | 0.092317 | 1.035 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 0.133691 | 0.874 | 0 | 0 |
| Formation of the nephric duct | R-HSA-9830364 | 0.040785 | 1.390 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 0.158025 | 0.801 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 0.106626 | 0.972 | 0 | 0 |
| Heme biosynthesis | R-HSA-189451 | 0.090604 | 1.043 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 0.116438 | 0.934 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 0.123160 | 0.910 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 0.161609 | 0.792 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 0.063018 | 1.201 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 0.140194 | 0.853 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 0.036312 | 1.440 | 0 | 0 |
| Amino acid transport across the plasma membrane | R-HSA-352230 | 0.150906 | 0.821 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 0.033984 | 1.469 | 0 | 0 |
| SLC-mediated transport of amino acids | R-HSA-9958863 | 0.179735 | 0.745 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 0.179347 | 0.746 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 0.056892 | 1.245 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 0.147371 | 0.832 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 0.179735 | 0.745 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 0.043174 | 1.365 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 0.049865 | 1.302 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 0.129974 | 0.886 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 0.058534 | 1.233 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 0.106601 | 0.972 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 0.106541 | 0.972 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 0.161609 | 0.792 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 0.096890 | 1.014 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 0.081418 | 1.089 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 0.123160 | 0.910 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 0.190755 | 0.720 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 0.068231 | 1.166 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 0.113113 | 0.946 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 0.158352 | 0.800 | 0 | 0 |
| Metabolism of polyamines | R-HSA-351202 | 0.154457 | 0.811 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 0.138969 | 0.857 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 0.066819 | 1.175 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 0.149694 | 0.825 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 0.194448 | 0.711 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 0.103296 | 0.986 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 0.096890 | 1.014 | 0 | 0 |
| Replication of the SARS-CoV-1 genome | R-HSA-9682706 | 0.159941 | 0.796 | 0 | 0 |
| Metabolism of porphyrins | R-HSA-189445 | 0.194448 | 0.711 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 0.154520 | 0.811 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 0.116438 | 0.934 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 0.116438 | 0.934 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 0.126556 | 0.898 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 0.190755 | 0.720 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 0.135927 | 0.867 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 0.135927 | 0.867 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 0.080315 | 1.095 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 0.096955 | 1.013 | 0 | 0 |
| SARS-CoV-1 Genome Replication and Transcription | R-HSA-9679514 | 0.168514 | 0.773 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 0.110051 | 0.958 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 0.158025 | 0.801 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 0.147121 | 0.832 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 0.180178 | 0.744 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 0.050475 | 1.297 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 0.192276 | 0.716 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 0.126556 | 0.898 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 0.106551 | 0.972 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 0.201863 | 0.695 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 0.201863 | 0.695 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 0.201863 | 0.695 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 0.201945 | 0.695 | 0 | 0 |
| Defective B3GAT3 causes JDSSDHD | R-HSA-3560801 | 0.201945 | 0.695 | 0 | 0 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | R-HSA-164938 | 0.201945 | 0.695 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 0.201945 | 0.695 | 0 | 0 |
| Replication of the SARS-CoV-2 genome | R-HSA-9694686 | 0.201945 | 0.695 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 0.205582 | 0.687 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 0.210092 | 0.678 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 0.210092 | 0.678 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 0.210092 | 0.678 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 0.210439 | 0.677 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 0.213043 | 0.672 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 0.218156 | 0.661 | 0 | 0 |
| SARS-CoV-2 Genome Replication and Transcription | R-HSA-9694682 | 0.218156 | 0.661 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 0.220530 | 0.657 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 0.220530 | 0.657 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 0.220530 | 0.657 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 0.224177 | 0.649 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 0.224282 | 0.649 | 0 | 0 |
| Formation of ATP by chemiosmotic coupling | R-HSA-163210 | 0.226139 | 0.646 | 0 | 0 |
| Signaling by NODAL | R-HSA-1181150 | 0.226139 | 0.646 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 0.226139 | 0.646 | 0 | 0 |
| Creatine metabolism | R-HSA-71288 | 0.226139 | 0.646 | 0 | 0 |
| Pregnenolone biosynthesis | R-HSA-196108 | 0.226139 | 0.646 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 0.226340 | 0.645 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 0.226410 | 0.645 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 0.228038 | 0.642 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 0.228510 | 0.641 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 0.234040 | 0.631 | 0 | 0 |
| Matriglycan biosynthesis on DAG1 | R-HSA-9939291 | 0.234040 | 0.631 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 0.234040 | 0.631 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 0.234040 | 0.631 | 0 | 0 |
| Prevention of phagosomal-lysosomal fusion | R-HSA-9636383 | 0.234040 | 0.631 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 0.235267 | 0.628 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 0.235565 | 0.628 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 0.239333 | 0.621 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 0.239333 | 0.621 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 0.239895 | 0.620 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 0.241861 | 0.616 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 0.241861 | 0.616 | 0 | 0 |
| Attachment and Entry | R-HSA-9694614 | 0.241861 | 0.616 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 0.241861 | 0.616 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 0.246880 | 0.608 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 0.248050 | 0.605 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 0.248260 | 0.605 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 0.249603 | 0.603 | 0 | 0 |
| Fructose metabolism | R-HSA-5652084 | 0.249603 | 0.603 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 0.249603 | 0.603 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 0.249603 | 0.603 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 0.250656 | 0.601 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 0.250656 | 0.601 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 0.250656 | 0.601 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 0.255485 | 0.593 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 0.257266 | 0.590 | 0 | 0 |
| Response of EIF2AK1 (HRI) to heme deficiency | R-HSA-9648895 | 0.257266 | 0.590 | 0 | 0 |
| Formation of the ureteric bud | R-HSA-9830674 | 0.257266 | 0.590 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 0.257266 | 0.590 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 0.257266 | 0.590 | 0 | 0 |
| Interleukin-20 family signaling | R-HSA-8854691 | 0.257266 | 0.590 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 0.261994 | 0.582 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 0.264852 | 0.577 | 0 | 0 |
| Complex III assembly | R-HSA-9865881 | 0.264852 | 0.577 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 0.264852 | 0.577 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 0.264852 | 0.577 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 0.269556 | 0.569 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 0.272360 | 0.565 | 1 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 0.272360 | 0.565 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 0.272360 | 0.565 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 0.272360 | 0.565 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 0.272753 | 0.564 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 0.273337 | 0.563 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 0.275516 | 0.560 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 0.277401 | 0.557 | 0 | 0 |
| Suppression of phagosomal maturation | R-HSA-9637687 | 0.279792 | 0.553 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 0.282466 | 0.549 | 1 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 0.284673 | 0.546 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 0.284673 | 0.546 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 0.287149 | 0.542 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 0.287149 | 0.542 | 0 | 0 |
| Signaling by BMP | R-HSA-201451 | 0.287149 | 0.542 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 0.287149 | 0.542 | 0 | 0 |
| Maturation of hRSV A proteins | R-HSA-9828806 | 0.287149 | 0.542 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 0.287149 | 0.542 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 0.294431 | 0.531 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 0.295993 | 0.529 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 0.299913 | 0.523 | 0 | 0 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | R-HSA-917729 | 0.301639 | 0.521 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 0.301639 | 0.521 | 0 | 0 |
| Regulation of pyruvate dehydrogenase (PDH) complex | R-HSA-204174 | 0.301639 | 0.521 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 0.301639 | 0.521 | 0 | 0 |
| DARPP-32 events | R-HSA-180024 | 0.301639 | 0.521 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 0.304519 | 0.516 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 0.306063 | 0.514 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 0.308774 | 0.510 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 0.308774 | 0.510 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 0.308774 | 0.510 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 0.312126 | 0.506 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 0.314799 | 0.502 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 0.314799 | 0.502 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 0.315836 | 0.501 | 0 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 0.315836 | 0.501 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 0.315836 | 0.501 | 0 | 0 |
| Cargo concentration in the ER | R-HSA-5694530 | 0.315836 | 0.501 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 0.315836 | 0.501 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 0.315836 | 0.501 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 0.315836 | 0.501 | 0 | 0 |
| Disease | R-HSA-1643685 | 0.316643 | 0.499 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 0.322292 | 0.492 | 0 | 0 |
| DAG1 glycosylations | R-HSA-8931838 | 0.322827 | 0.491 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 0.322827 | 0.491 | 0 | 0 |
| Developmental Lineage of Multipotent Pancreatic Progenitor Cells | R-HSA-9937080 | 0.322827 | 0.491 | 0 | 0 |
| HS-GAG degradation | R-HSA-2024096 | 0.322827 | 0.491 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 0.327955 | 0.484 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 0.329747 | 0.482 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 0.329747 | 0.482 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 0.329747 | 0.482 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 0.329747 | 0.482 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 0.329747 | 0.482 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 0.329747 | 0.482 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 0.329747 | 0.482 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 0.329747 | 0.482 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 0.329766 | 0.482 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 0.333494 | 0.477 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 0.336596 | 0.473 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 0.336596 | 0.473 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 0.336596 | 0.473 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 0.342325 | 0.466 | 0 | 0 |
| Glycosaminoglycan-protein linkage region biosynthesis | R-HSA-1971475 | 0.343376 | 0.464 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 0.343376 | 0.464 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 0.343376 | 0.464 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 0.344643 | 0.463 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 0.347237 | 0.459 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 0.350087 | 0.456 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 0.352042 | 0.453 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 0.352042 | 0.453 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 0.356253 | 0.448 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 0.356730 | 0.448 | 0 | 0 |
| HS-GAG biosynthesis | R-HSA-2022928 | 0.356730 | 0.448 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 0.356730 | 0.448 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 0.356730 | 0.448 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 0.356730 | 0.448 | 0 | 0 |
| Triglyceride catabolism | R-HSA-163560 | 0.356730 | 0.448 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 0.356730 | 0.448 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 0.363088 | 0.440 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 0.363088 | 0.440 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 0.363305 | 0.440 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 0.363305 | 0.440 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 0.363305 | 0.440 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 0.369814 | 0.432 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 0.370145 | 0.432 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 0.376256 | 0.425 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 0.377704 | 0.423 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 0.381337 | 0.419 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 0.382633 | 0.417 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 0.382633 | 0.417 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 0.382633 | 0.417 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 0.382633 | 0.417 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 0.385933 | 0.413 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 0.388576 | 0.411 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 0.388945 | 0.410 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 0.388945 | 0.410 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 0.389501 | 0.409 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 0.395007 | 0.403 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 0.395193 | 0.403 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 0.395193 | 0.403 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 0.395193 | 0.403 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 0.395882 | 0.402 | 0 | 0 |
| M Phase | R-HSA-68886 | 0.396729 | 0.402 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 0.401377 | 0.396 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 0.401377 | 0.396 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 0.402941 | 0.395 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 0.402941 | 0.395 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 0.407499 | 0.390 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 0.413558 | 0.383 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 0.413558 | 0.383 | 1 | 1 |
| Surfactant metabolism | R-HSA-5683826 | 0.413558 | 0.383 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 0.413558 | 0.383 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 0.413558 | 0.383 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 0.413611 | 0.383 | 0 | 0 |
| Diseases associated with glycosaminoglycan metabolism | R-HSA-3560782 | 0.419556 | 0.377 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 0.419556 | 0.377 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 0.419556 | 0.377 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 0.425039 | 0.372 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 0.425493 | 0.371 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 0.425493 | 0.371 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 0.425493 | 0.371 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 0.425493 | 0.371 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 0.425493 | 0.371 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 0.425493 | 0.371 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 0.425493 | 0.371 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 0.427689 | 0.369 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 0.431369 | 0.365 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 0.431369 | 0.365 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 0.431369 | 0.365 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 0.445036 | 0.352 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 0.445036 | 0.352 | 0 | 0 |
| Azathioprine ADME | R-HSA-9748787 | 0.448643 | 0.348 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 0.449230 | 0.348 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 0.451894 | 0.345 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 0.459867 | 0.337 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 0.459867 | 0.337 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 0.459867 | 0.337 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 0.459867 | 0.337 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 0.465394 | 0.332 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 0.465465 | 0.332 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 0.465465 | 0.332 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 0.467764 | 0.330 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 0.470865 | 0.327 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 0.472176 | 0.326 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 0.472176 | 0.326 | 0 | 0 |
| Cell Cycle | R-HSA-1640170 | 0.472513 | 0.326 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 0.475513 | 0.323 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 0.476280 | 0.322 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 0.476280 | 0.322 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 0.476280 | 0.322 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 0.478231 | 0.320 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 0.481640 | 0.317 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 0.481640 | 0.317 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 0.481640 | 0.317 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 0.482148 | 0.317 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 0.485444 | 0.314 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 0.486945 | 0.313 | 0 | 0 |
| Synthesis of PA | R-HSA-1483166 | 0.486945 | 0.313 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 0.491182 | 0.309 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 0.492005 | 0.308 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 0.492197 | 0.308 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 0.495264 | 0.305 | 0 | 0 |
| Heparan sulfate/heparin (HS-GAG) metabolism | R-HSA-1638091 | 0.497395 | 0.303 | 0 | 0 |
| Triglyceride metabolism | R-HSA-8979227 | 0.497395 | 0.303 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 0.497395 | 0.303 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 0.507633 | 0.294 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 0.512674 | 0.290 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 0.512674 | 0.290 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 0.512674 | 0.290 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 0.512674 | 0.290 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 0.514541 | 0.289 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 0.517663 | 0.286 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 0.517663 | 0.286 | 0 | 0 |
| Complex I biogenesis | R-HSA-6799198 | 0.517663 | 0.286 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 0.517663 | 0.286 | 1 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 0.517663 | 0.286 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 0.517663 | 0.286 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 0.517663 | 0.286 | 0 | 0 |
| CD22 mediated BCR regulation | R-HSA-5690714 | 0.522602 | 0.282 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 0.522602 | 0.282 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 0.523998 | 0.281 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 0.527122 | 0.278 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 0.527491 | 0.278 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 0.532330 | 0.274 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 0.533330 | 0.273 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 0.537119 | 0.270 | 0 | 0 |
| Metabolism of steroid hormones | R-HSA-196071 | 0.537119 | 0.270 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 0.537119 | 0.270 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 0.541860 | 0.266 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 0.541860 | 0.266 | 0 | 0 |
| Fatty acyl-CoA biosynthesis | R-HSA-75105 | 0.551197 | 0.259 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 0.555795 | 0.255 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 0.555795 | 0.255 | 0 | 0 |
| Retinoid metabolism and transport | R-HSA-975634 | 0.555795 | 0.255 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 0.555795 | 0.255 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 0.560345 | 0.252 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 0.564850 | 0.248 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 0.573721 | 0.241 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 0.573721 | 0.241 | 0 | 0 |
| Iron uptake and transport | R-HSA-917937 | 0.573721 | 0.241 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 0.578089 | 0.238 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 0.583833 | 0.234 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 0.586693 | 0.232 | 0 | 0 |
| Cholesterol biosynthesis | R-HSA-191273 | 0.586693 | 0.232 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 0.595121 | 0.225 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 0.595121 | 0.225 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 0.595121 | 0.225 | 0 | 0 |
| Metabolism of fat-soluble vitamins | R-HSA-6806667 | 0.599272 | 0.222 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 0.599272 | 0.222 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 0.606178 | 0.217 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 0.609584 | 0.215 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 0.611470 | 0.214 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 0.615453 | 0.211 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 0.615453 | 0.211 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 0.617007 | 0.210 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 0.627162 | 0.203 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 0.627162 | 0.203 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 0.630223 | 0.201 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 0.630986 | 0.200 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 0.630986 | 0.200 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 0.634713 | 0.197 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 0.637982 | 0.195 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 0.638516 | 0.195 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 0.642224 | 0.192 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 0.656681 | 0.183 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 0.658051 | 0.182 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 0.660204 | 0.180 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 0.667142 | 0.176 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 0.667142 | 0.176 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 0.667142 | 0.176 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 0.673939 | 0.171 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 0.674878 | 0.171 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 0.679098 | 0.168 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 0.680598 | 0.167 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 0.683876 | 0.165 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 0.684834 | 0.164 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 0.685623 | 0.164 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 0.687122 | 0.163 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 0.691031 | 0.161 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 0.693513 | 0.159 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 0.693513 | 0.159 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 0.702857 | 0.153 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 0.708929 | 0.149 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 0.708929 | 0.149 | 0 | 0 |
| Antimicrobial peptides | R-HSA-6803157 | 0.717806 | 0.144 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 0.720705 | 0.142 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 0.723575 | 0.141 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 0.726415 | 0.139 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 0.737487 | 0.132 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 0.737487 | 0.132 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 0.740185 | 0.131 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 0.742855 | 0.129 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 0.749644 | 0.125 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 0.750704 | 0.125 | 0 | 0 |
| Sensory perception of sweet, bitter, and umami (glutamate) taste | R-HSA-9717207 | 0.755803 | 0.122 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 0.755803 | 0.122 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 0.760337 | 0.119 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 0.763259 | 0.117 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 0.763259 | 0.117 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 0.763259 | 0.117 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 0.765693 | 0.116 | 0 | 0 |
| Sensory perception of taste | R-HSA-9717189 | 0.779787 | 0.108 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 0.782052 | 0.107 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 0.782052 | 0.107 | 0 | 0 |
| O-linked glycosylation | R-HSA-5173105 | 0.795167 | 0.100 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 0.811539 | 0.091 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 0.817207 | 0.088 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 0.826429 | 0.083 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 0.828218 | 0.082 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 0.828218 | 0.082 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 0.829988 | 0.081 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 0.831740 | 0.080 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 0.834663 | 0.078 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 0.835189 | 0.078 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 0.836888 | 0.077 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 0.840229 | 0.076 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 0.840233 | 0.076 | 0 | 0 |
| Translation | R-HSA-72766 | 0.842410 | 0.074 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 0.856878 | 0.067 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 0.857448 | 0.067 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 0.861814 | 0.065 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 0.861814 | 0.065 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 0.864651 | 0.063 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 0.868513 | 0.061 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 0.869524 | 0.061 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 0.877498 | 0.057 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 0.884160 | 0.053 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 0.887712 | 0.052 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 0.898790 | 0.046 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 0.908781 | 0.042 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 0.914298 | 0.039 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 0.922206 | 0.035 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 0.927442 | 0.033 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 0.929613 | 0.032 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 0.929673 | 0.032 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 0.935375 | 0.029 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 0.937937 | 0.028 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 0.946365 | 0.024 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 0.946922 | 0.024 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 0.961209 | 0.017 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 0.961598 | 0.017 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 0.961953 | 0.017 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 0.964909 | 0.016 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 0.971348 | 0.013 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 0.980559 | 0.009 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 0.981134 | 0.008 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 0.981161 | 0.008 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 0.981358 | 0.008 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 0.988261 | 0.005 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 0.998603 | 0.001 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 0.999170 | 0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 0.999565 | 0.000 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 1.000000 | 0.000 | 1 | 1 |
Top15 pathways (red highlights are reference pathways)
Compared with reference pathways
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| HSF1 activation | R-HSA-3371511 | 1.110223e-16 | 15.955 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 1.110223e-16 | 15.955 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 1.110223e-16 | 15.955 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 1.110223e-16 | 15.955 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 1.110223e-16 | 15.955 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 3.903544e-13 | 12.409 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 1.000533e-12 | 12.000 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 5.759948e-12 | 11.240 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 9.478129e-11 | 10.023 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 3.567785e-10 | 9.448 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 3.703524e-10 | 9.431 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 8.609020e-10 | 9.065 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 2.147081e-09 | 8.668 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 3.045112e-09 | 8.516 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 2.981486e-09 | 8.526 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 3.823139e-09 | 8.418 | 1 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 6.974319e-09 | 8.156 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 1.724927e-08 | 7.763 | 1 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 2.048859e-08 | 7.688 | 0 | 0 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | R-HSA-75035 | 3.417090e-08 | 7.466 | 0 | 0 |
| Activation of BAD and translocation to mitochondria | R-HSA-111447 | 7.220595e-08 | 7.141 | 0 | 0 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | R-HSA-9755779 | 7.220595e-08 | 7.141 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 8.434276e-08 | 7.074 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 8.155204e-08 | 7.089 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 1.427844e-07 | 6.845 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 1.427844e-07 | 6.845 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 2.659445e-07 | 6.575 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 3.742129e-07 | 6.427 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 3.742129e-07 | 6.427 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 4.493038e-07 | 6.347 | 1 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 7.668352e-07 | 6.115 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 1.542477e-06 | 5.812 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 1.618331e-06 | 5.791 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 2.348894e-06 | 5.629 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 2.698278e-06 | 5.569 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 2.820150e-06 | 5.550 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 3.430758e-06 | 5.465 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 4.060853e-06 | 5.391 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 4.525906e-06 | 5.344 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 4.889865e-06 | 5.311 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 5.650422e-06 | 5.248 | 1 | 1 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 5.834569e-06 | 5.234 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 6.001293e-06 | 5.222 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 6.162884e-06 | 5.210 | 0 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 6.455277e-06 | 5.190 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 9.445968e-06 | 5.025 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 1.360041e-05 | 4.866 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 1.345784e-05 | 4.871 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 1.496243e-05 | 4.825 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 1.651140e-05 | 4.782 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 1.761160e-05 | 4.754 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 1.745134e-05 | 4.758 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 1.763029e-05 | 4.754 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 1.879714e-05 | 4.726 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 1.879714e-05 | 4.726 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 2.693607e-05 | 4.570 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 2.693607e-05 | 4.570 | 0 | 0 |
| Translation | R-HSA-72766 | 2.594858e-05 | 4.586 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 2.571221e-05 | 4.590 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 3.442179e-05 | 4.463 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 4.255743e-05 | 4.371 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 4.451608e-05 | 4.351 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 4.924435e-05 | 4.308 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 5.506188e-05 | 4.259 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 5.552051e-05 | 4.256 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 6.180748e-05 | 4.209 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 6.777521e-05 | 4.169 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 6.999605e-05 | 4.155 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 7.093320e-05 | 4.149 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 7.107015e-05 | 4.148 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 7.910358e-05 | 4.102 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 7.649242e-05 | 4.116 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 8.263890e-05 | 4.083 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 8.937144e-05 | 4.049 | 0 | 0 |
| Folding of actin by CCT/TriC | R-HSA-390450 | 9.932173e-05 | 4.003 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 9.772499e-05 | 4.010 | 1 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 1.201983e-04 | 3.920 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 1.435336e-04 | 3.843 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 1.365536e-04 | 3.865 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 1.373539e-04 | 3.862 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 1.481815e-04 | 3.829 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 1.731593e-04 | 3.762 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 1.797543e-04 | 3.745 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 1.878552e-04 | 3.726 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 1.979883e-04 | 3.703 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 2.069107e-04 | 3.684 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 2.165303e-04 | 3.664 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 2.165303e-04 | 3.664 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 2.192465e-04 | 3.659 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 2.868907e-04 | 3.542 | 0 | 0 |
| FLT3 signaling by CBL mutants | R-HSA-9706377 | 2.950042e-04 | 3.530 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 3.198362e-04 | 3.495 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 3.413048e-04 | 3.467 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 3.935633e-04 | 3.405 | 0 | 0 |
| Protein methylation | R-HSA-8876725 | 4.167203e-04 | 3.380 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 4.167203e-04 | 3.380 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 4.224192e-04 | 3.374 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 4.292598e-04 | 3.367 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 5.274732e-04 | 3.278 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 5.361105e-04 | 3.271 | 1 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 5.876571e-04 | 3.231 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 5.787678e-04 | 3.237 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 5.962478e-04 | 3.225 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 7.509115e-04 | 3.124 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 7.773685e-04 | 3.109 | 0 | 0 |
| Uptake and function of diphtheria toxin | R-HSA-5336415 | 8.267312e-04 | 3.083 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 8.431888e-04 | 3.074 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 9.894747e-04 | 3.005 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 1.059839e-03 | 2.975 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 1.078802e-03 | 2.967 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 1.281941e-03 | 2.892 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 1.325470e-03 | 2.878 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 1.497631e-03 | 2.825 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 1.551731e-03 | 2.809 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 1.733962e-03 | 2.761 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 1.792988e-03 | 2.746 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 1.851479e-03 | 2.732 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 2.043485e-03 | 2.690 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 2.043485e-03 | 2.690 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 2.432434e-03 | 2.614 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 2.432434e-03 | 2.614 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 2.432434e-03 | 2.614 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 2.432434e-03 | 2.614 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 2.432434e-03 | 2.614 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 2.432434e-03 | 2.614 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 2.432434e-03 | 2.614 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 2.432434e-03 | 2.614 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 2.432434e-03 | 2.614 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 2.432434e-03 | 2.614 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 2.432434e-03 | 2.614 | 0 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 2.222482e-03 | 2.653 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 2.206895e-03 | 2.656 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 2.220225e-03 | 2.654 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 2.509840e-03 | 2.600 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 3.129821e-03 | 2.504 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 3.091826e-03 | 2.510 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 3.091826e-03 | 2.510 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 3.091826e-03 | 2.510 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 3.091826e-03 | 2.510 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 2.862664e-03 | 2.543 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 3.121438e-03 | 2.506 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 3.246216e-03 | 2.489 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 3.449777e-03 | 2.462 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 3.841965e-03 | 2.415 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 4.215573e-03 | 2.375 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 4.241193e-03 | 2.373 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 4.275170e-03 | 2.369 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 4.568851e-03 | 2.340 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 4.667511e-03 | 2.331 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 4.818125e-03 | 2.317 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 5.039487e-03 | 2.298 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 5.058315e-03 | 2.296 | 0 | 0 |
| FLT3 signaling through SRC family kinases | R-HSA-9706374 | 5.345807e-03 | 2.272 | 0 | 0 |
| MTF1 activates gene expression | R-HSA-5660489 | 5.345807e-03 | 2.272 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 5.801599e-03 | 2.236 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 6.117052e-03 | 2.213 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 6.659677e-03 | 2.177 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 7.040861e-03 | 2.152 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 8.153937e-03 | 2.089 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 7.838516e-03 | 2.106 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 8.214630e-03 | 2.085 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 7.361067e-03 | 2.133 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 7.105093e-03 | 2.148 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 8.476130e-03 | 2.072 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 8.551567e-03 | 2.068 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 8.656499e-03 | 2.063 | 0 | 0 |
| VEGF binds to VEGFR leading to receptor dimerization | R-HSA-195399 | 9.283472e-03 | 2.032 | 0 | 0 |
| Aryl hydrocarbon receptor signalling | R-HSA-8937144 | 9.283472e-03 | 2.032 | 0 | 0 |
| VEGF ligand-receptor interactions | R-HSA-194313 | 9.283472e-03 | 2.032 | 0 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 9.283472e-03 | 2.032 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 9.531912e-03 | 2.021 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 9.531912e-03 | 2.021 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 9.531912e-03 | 2.021 | 1 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 9.851072e-03 | 2.007 | 0 | 0 |
| Disease | R-HSA-1643685 | 1.023812e-02 | 1.990 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 1.058966e-02 | 1.975 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 1.058966e-02 | 1.975 | 0 | 0 |
| Protein folding | R-HSA-391251 | 1.075051e-02 | 1.969 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 1.178907e-02 | 1.929 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 1.178907e-02 | 1.929 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 1.301694e-02 | 1.885 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 1.123421e-02 | 1.949 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 1.136313e-02 | 1.945 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 1.136313e-02 | 1.945 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 1.136313e-02 | 1.945 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 1.217204e-02 | 1.915 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 1.217204e-02 | 1.915 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 1.161279e-02 | 1.935 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 1.301694e-02 | 1.885 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 1.157726e-02 | 1.936 | 0 | 0 |
| Immune System | R-HSA-168256 | 1.379468e-02 | 1.860 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 1.389836e-02 | 1.857 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 1.398618e-02 | 1.854 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 1.401212e-02 | 1.853 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 1.481679e-02 | 1.829 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 1.566972e-02 | 1.805 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 1.577270e-02 | 1.802 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 1.577270e-02 | 1.802 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 1.577270e-02 | 1.802 | 0 | 0 |
| Drug resistance of FLT3 mutants | R-HSA-9702506 | 1.772643e-02 | 1.751 | 0 | 0 |
| FLT3 mutants bind TKIs | R-HSA-9702509 | 1.772643e-02 | 1.751 | 0 | 0 |
| tamatinib-resistant FLT3 mutants | R-HSA-9703009 | 1.772643e-02 | 1.751 | 0 | 0 |
| lestaurtinib-resistant FLT3 mutants | R-HSA-9702596 | 1.772643e-02 | 1.751 | 0 | 0 |
| gilteritinib-resistant FLT3 mutants | R-HSA-9702590 | 1.772643e-02 | 1.751 | 0 | 0 |
| midostaurin-resistant FLT3 mutants | R-HSA-9702600 | 1.772643e-02 | 1.751 | 0 | 0 |
| KW2449-resistant FLT3 mutants | R-HSA-9702569 | 1.772643e-02 | 1.751 | 0 | 0 |
| semaxanib-resistant FLT3 mutants | R-HSA-9702577 | 1.772643e-02 | 1.751 | 0 | 0 |
| linifanib-resistant FLT3 mutants | R-HSA-9702998 | 1.772643e-02 | 1.751 | 0 | 0 |
| sunitinib-resistant FLT3 mutants | R-HSA-9702632 | 1.772643e-02 | 1.751 | 0 | 0 |
| crenolanib-resistant FLT3 mutants | R-HSA-9702581 | 1.772643e-02 | 1.751 | 0 | 0 |
| ponatinib-resistant FLT3 mutants | R-HSA-9702614 | 1.772643e-02 | 1.751 | 0 | 0 |
| quizartinib-resistant FLT3 mutants | R-HSA-9702620 | 1.772643e-02 | 1.751 | 0 | 0 |
| sorafenib-resistant FLT3 mutants | R-HSA-9702624 | 1.772643e-02 | 1.751 | 0 | 0 |
| tandutinib-resistant FLT3 mutants | R-HSA-9702636 | 1.772643e-02 | 1.751 | 0 | 0 |
| pexidartinib-resistant FLT3 mutants | R-HSA-9702605 | 1.772643e-02 | 1.751 | 0 | 0 |
| Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | R-HSA-9828211 | 1.694735e-02 | 1.771 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 1.694735e-02 | 1.771 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 1.993530e-02 | 1.700 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 1.598593e-02 | 1.796 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 1.755597e-02 | 1.756 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 1.993530e-02 | 1.700 | 0 | 0 |
| Adrenoceptors | R-HSA-390696 | 1.694735e-02 | 1.771 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 1.993530e-02 | 1.700 | 0 | 0 |
| Inactivation of CDC42 and RAC1 | R-HSA-428543 | 1.993530e-02 | 1.700 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 1.828829e-02 | 1.738 | 0 | 0 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | R-HSA-8849469 | 1.694735e-02 | 1.771 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 1.694735e-02 | 1.771 | 0 | 0 |
| Respiratory syncytial virus genome replication | R-HSA-9834752 | 1.993530e-02 | 1.700 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 1.676654e-02 | 1.776 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 1.997969e-02 | 1.699 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 2.033761e-02 | 1.692 | 0 | 0 |
| Azathioprine ADME | R-HSA-9748787 | 2.112920e-02 | 1.675 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 2.196385e-02 | 1.658 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 2.201873e-02 | 1.657 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 2.231848e-02 | 1.651 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 2.268290e-02 | 1.644 | 0 | 0 |
| Cell Cycle | R-HSA-1640170 | 2.286626e-02 | 1.641 | 0 | 0 |
| Assembly and release of respiratory syncytial virus (RSV) virions | R-HSA-9820962 | 2.312589e-02 | 1.636 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 2.312589e-02 | 1.636 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 2.409524e-02 | 1.618 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 2.409524e-02 | 1.618 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 2.409524e-02 | 1.618 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 2.560185e-02 | 1.592 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 2.651104e-02 | 1.577 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 2.693054e-02 | 1.570 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 2.750370e-02 | 1.561 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 2.750370e-02 | 1.561 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 2.767692e-02 | 1.558 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 2.801345e-02 | 1.553 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 2.887124e-02 | 1.540 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 2.947886e-02 | 1.530 | 0 | 0 |
| Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | R-HSA-9824878 | 3.008291e-02 | 1.522 | 0 | 0 |
| TICAM1-dependent activation of IRF3/IRF7 | R-HSA-9013973 | 3.008291e-02 | 1.522 | 0 | 0 |
| NFE2L2 regulates pentose phosphate pathway genes | R-HSA-9818028 | 3.008291e-02 | 1.522 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 3.026128e-02 | 1.519 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH6 | R-HSA-5632968 | 3.513970e-02 | 1.454 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 3.383387e-02 | 1.471 | 0 | 0 |
| Scavenging by Class F Receptors | R-HSA-3000484 | 3.383387e-02 | 1.471 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 3.142654e-02 | 1.503 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 3.950688e-02 | 1.403 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 3.364800e-02 | 1.473 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 3.384053e-02 | 1.471 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 3.810648e-02 | 1.419 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 3.383387e-02 | 1.471 | 0 | 0 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | R-HSA-6814122 | 3.810648e-02 | 1.419 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 4.044308e-02 | 1.393 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 4.044308e-02 | 1.393 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 3.261958e-02 | 1.487 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 3.775649e-02 | 1.423 | 0 | 0 |
| Inhibition of PKR | R-HSA-169131 | 3.513970e-02 | 1.454 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 3.584129e-02 | 1.446 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 3.810648e-02 | 1.419 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 4.044308e-02 | 1.393 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 3.476638e-02 | 1.459 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 3.158713e-02 | 1.500 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 3.645296e-02 | 1.438 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9683610 | 3.775649e-02 | 1.423 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 3.977729e-02 | 1.400 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 3.376639e-02 | 1.472 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 3.476638e-02 | 1.459 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 3.385055e-02 | 1.470 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 3.383387e-02 | 1.471 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 3.273801e-02 | 1.485 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 3.295094e-02 | 1.482 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 3.152706e-02 | 1.501 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 4.184354e-02 | 1.378 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 4.285055e-02 | 1.368 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 4.285055e-02 | 1.368 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 4.532828e-02 | 1.344 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 4.532828e-02 | 1.344 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 4.608802e-02 | 1.336 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 4.608802e-02 | 1.336 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 4.631740e-02 | 1.334 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 4.631740e-02 | 1.334 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 4.914611e-02 | 1.309 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 5.025262e-02 | 1.299 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 5.048310e-02 | 1.297 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 5.048310e-02 | 1.297 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 5.049189e-02 | 1.297 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 5.049189e-02 | 1.297 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 5.071004e-02 | 1.295 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 5.075298e-02 | 1.295 | 0 | 0 |
| Abasic sugar-phosphate removal via the single-nucleotide replacement pathway | R-HSA-73930 | 5.224533e-02 | 1.282 | 0 | 0 |
| Manipulation of host energy metabolism | R-HSA-9636667 | 5.224533e-02 | 1.282 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH2 | R-HSA-5632928 | 5.224533e-02 | 1.282 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 5.272800e-02 | 1.278 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 5.316058e-02 | 1.274 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 5.317634e-02 | 1.274 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 5.474442e-02 | 1.262 | 0 | 0 |
| Antigen processing: Ub, ATP-independent proteasomal degradation | R-HSA-9912633 | 5.502214e-02 | 1.259 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | R-HSA-6804114 | 5.502214e-02 | 1.259 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 5.502214e-02 | 1.259 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 5.502214e-02 | 1.259 | 0 | 0 |
| Response to metal ions | R-HSA-5660526 | 5.502214e-02 | 1.259 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 5.592822e-02 | 1.252 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 5.592822e-02 | 1.252 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 5.592822e-02 | 1.252 | 0 | 0 |
| Signaling by cytosolic PDGFRA and PDGFRB fusion proteins | R-HSA-9673766 | 8.555524e-02 | 1.068 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 5.969871e-02 | 1.224 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 5.969871e-02 | 1.224 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 5.969871e-02 | 1.224 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 6.450653e-02 | 1.190 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 8.493125e-02 | 1.071 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 8.493125e-02 | 1.071 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 7.380759e-02 | 1.132 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 5.874671e-02 | 1.231 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 5.918185e-02 | 1.228 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 7.066936e-02 | 1.151 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 5.874671e-02 | 1.231 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 7.700692e-02 | 1.113 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 6.544191e-02 | 1.184 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 7.449178e-02 | 1.128 | 0 | 0 |
| Inactivation of CSF3 (G-CSF) signaling | R-HSA-9705462 | 8.493125e-02 | 1.071 | 0 | 0 |
| Neurophilin interactions with VEGF and VEGFR | R-HSA-194306 | 6.904874e-02 | 1.161 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 5.874671e-02 | 1.231 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 8.493125e-02 | 1.071 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 8.696125e-02 | 1.061 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 6.759320e-02 | 1.170 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 7.700692e-02 | 1.113 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 6.759320e-02 | 1.170 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 7.000449e-02 | 1.155 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 6.395632e-02 | 1.194 | 0 | 0 |
| Diseases of Mismatch Repair (MMR) | R-HSA-5423599 | 8.555524e-02 | 1.068 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 6.519368e-02 | 1.186 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 6.608745e-02 | 1.180 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 6.322096e-02 | 1.199 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 8.358479e-02 | 1.078 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 5.890085e-02 | 1.230 | 0 | 0 |
| M Phase | R-HSA-68886 | 6.086592e-02 | 1.216 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 6.458009e-02 | 1.190 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 6.759320e-02 | 1.170 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 7.066936e-02 | 1.151 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 6.642994e-02 | 1.178 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 8.493125e-02 | 1.071 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 6.943952e-02 | 1.158 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 7.066936e-02 | 1.151 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 7.380759e-02 | 1.132 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 7.380759e-02 | 1.132 | 0 | 0 |
| Protein hydroxylation | R-HSA-9629569 | 7.449178e-02 | 1.128 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 7.472632e-02 | 1.127 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 8.358479e-02 | 1.078 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 8.358479e-02 | 1.078 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 5.915443e-02 | 1.228 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 8.493125e-02 | 1.071 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 7.472632e-02 | 1.127 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 7.449178e-02 | 1.128 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 6.943952e-02 | 1.158 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 5.914273e-02 | 1.228 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 6.458009e-02 | 1.190 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 8.026633e-02 | 1.095 | 0 | 0 |
| Specification of primordial germ cells | R-HSA-9827857 | 5.969871e-02 | 1.224 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 7.655670e-02 | 1.116 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9683701 | 5.874671e-02 | 1.231 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 7.449178e-02 | 1.128 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 8.874366e-02 | 1.052 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 9.030747e-02 | 1.044 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 9.030747e-02 | 1.044 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 9.039464e-02 | 1.044 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 9.039464e-02 | 1.044 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 9.119330e-02 | 1.040 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 9.388388e-02 | 1.027 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 9.388388e-02 | 1.027 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 9.388388e-02 | 1.027 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 9.388388e-02 | 1.027 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 9.515863e-02 | 1.022 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 9.578095e-02 | 1.019 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 9.742788e-02 | 1.011 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 9.742788e-02 | 1.011 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 9.742788e-02 | 1.011 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 9.742788e-02 | 1.011 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 9.742788e-02 | 1.011 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 9.775086e-02 | 1.010 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 9.841136e-02 | 1.007 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 1.010255e-01 | 0.996 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 1.013466e-01 | 0.994 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 1.013466e-01 | 0.994 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 1.013466e-01 | 0.994 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 1.013466e-01 | 0.994 | 0 | 0 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 1.017701e-01 | 0.992 | 0 | 0 |
| GRB7 events in ERBB2 signaling | R-HSA-1306955 | 1.017701e-01 | 0.992 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 1.017701e-01 | 0.992 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 1.017701e-01 | 0.992 | 0 | 0 |
| NADE modulates death signalling | R-HSA-205025 | 1.017701e-01 | 0.992 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 1.046757e-01 | 0.980 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 1.061676e-01 | 0.974 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 1.069994e-01 | 0.971 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 1.069994e-01 | 0.971 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 1.079426e-01 | 0.967 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 1.083772e-01 | 0.965 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 1.083772e-01 | 0.965 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 1.106110e-01 | 0.956 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 1.132955e-01 | 0.946 | 0 | 0 |
| Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | R-HSA-9673768 | 1.176984e-01 | 0.929 | 0 | 0 |
| STAT5 Activation | R-HSA-9645135 | 1.487154e-01 | 0.828 | 0 | 0 |
| Displacement of DNA glycosylase by APEX1 | R-HSA-110357 | 1.638140e-01 | 0.786 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 1.638140e-01 | 0.786 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 1.638140e-01 | 0.786 | 0 | 0 |
| ALKBH3 mediated reversal of alkylation damage | R-HSA-112126 | 1.786457e-01 | 0.748 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 1.786457e-01 | 0.748 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 1.786457e-01 | 0.748 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 1.932153e-01 | 0.714 | 0 | 0 |
| Lipophagy | R-HSA-9613354 | 1.932153e-01 | 0.714 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 2.075273e-01 | 0.683 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 2.215862e-01 | 0.654 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 2.215862e-01 | 0.654 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 2.215862e-01 | 0.654 | 0 | 0 |
| Synthesis of diphthamide-EEF2 | R-HSA-5358493 | 2.353966e-01 | 0.628 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 2.353966e-01 | 0.628 | 0 | 0 |
| Cristae formation | R-HSA-8949613 | 1.185475e-01 | 0.926 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 1.303884e-01 | 0.885 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 1.673318e-01 | 0.776 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 1.239563e-01 | 0.907 | 0 | 0 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | R-HSA-9014325 | 2.075273e-01 | 0.683 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 1.364077e-01 | 0.865 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex | R-HSA-937042 | 1.932153e-01 | 0.714 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 1.610494e-01 | 0.793 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 1.231668e-01 | 0.910 | 0 | 0 |
| Binding and entry of HIV virion | R-HSA-173107 | 2.075273e-01 | 0.683 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 1.424875e-01 | 0.846 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 1.244335e-01 | 0.905 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 1.303884e-01 | 0.885 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 1.638140e-01 | 0.786 | 0 | 0 |
| Myoclonic epilepsy of Lafora | R-HSA-3785653 | 1.786457e-01 | 0.748 | 0 | 0 |
| Josephin domain DUBs | R-HSA-5689877 | 2.075273e-01 | 0.683 | 0 | 0 |
| vRNP Assembly | R-HSA-192905 | 2.215862e-01 | 0.654 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 2.215862e-01 | 0.654 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 2.353966e-01 | 0.628 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 2.353966e-01 | 0.628 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 2.353966e-01 | 0.628 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 1.185475e-01 | 0.926 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 1.179249e-01 | 0.928 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 1.460535e-01 | 0.835 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 2.015376e-01 | 0.696 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 1.756758e-01 | 0.755 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 1.937638e-01 | 0.713 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 1.548122e-01 | 0.810 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 1.316009e-01 | 0.881 | 0 | 0 |
| Downregulation of ERBB4 signaling | R-HSA-1253288 | 1.786457e-01 | 0.748 | 0 | 0 |
| Activation of the AP-1 family of transcription factors | R-HSA-450341 | 1.932153e-01 | 0.714 | 0 | 0 |
| Alpha-protein kinase 1 signaling pathway | R-HSA-9645460 | 2.215862e-01 | 0.654 | 0 | 0 |
| Chylomicron assembly | R-HSA-8963888 | 2.215862e-01 | 0.654 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 1.185475e-01 | 0.926 | 0 | 0 |
| Developmental Lineage of Multipotent Pancreatic Progenitor Cells | R-HSA-9937080 | 1.486236e-01 | 0.828 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 1.692775e-01 | 0.771 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 1.692775e-01 | 0.771 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 1.780402e-01 | 0.749 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 1.244335e-01 | 0.905 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 1.244335e-01 | 0.905 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 1.303884e-01 | 0.885 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 1.673318e-01 | 0.776 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 1.741688e-01 | 0.759 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 1.564240e-01 | 0.806 | 0 | 0 |
| Resolution of AP sites via the single-nucleotide replacement pathway | R-HSA-110381 | 1.176984e-01 | 0.929 | 0 | 0 |
| LDL remodeling | R-HSA-8964041 | 1.638140e-01 | 0.786 | 0 | 0 |
| Regulation of signaling by NODAL | R-HSA-1433617 | 1.932153e-01 | 0.714 | 0 | 0 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | R-HSA-428359 | 2.075273e-01 | 0.683 | 0 | 0 |
| Viral RNP Complexes in the Host Cell Nucleus | R-HSA-168330 | 2.353966e-01 | 0.628 | 0 | 0 |
| Regulation of ornithine decarboxylase (ODC) | R-HSA-350562 | 1.486236e-01 | 0.828 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 1.548122e-01 | 0.810 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 1.736430e-01 | 0.760 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 1.736556e-01 | 0.760 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 1.928425e-01 | 0.715 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 1.864142e-01 | 0.730 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 1.548122e-01 | 0.810 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 1.864142e-01 | 0.730 | 0 | 0 |
| Cross-presentation of soluble exogenous antigens (endosomes) | R-HSA-1236978 | 1.992992e-01 | 0.700 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 2.319069e-01 | 0.635 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 2.004602e-01 | 0.698 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 1.673318e-01 | 0.776 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 2.353966e-01 | 0.628 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 1.424875e-01 | 0.846 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 2.096101e-01 | 0.679 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 1.968408e-01 | 0.706 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 2.351409e-01 | 0.629 | 0 | 0 |
| S Phase | R-HSA-69242 | 1.786444e-01 | 0.748 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 2.188101e-01 | 0.660 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 1.590411e-01 | 0.798 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 2.319069e-01 | 0.635 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 1.559637e-01 | 0.807 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 1.932153e-01 | 0.714 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 1.309948e-01 | 0.883 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 1.970904e-01 | 0.705 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 2.272155e-01 | 0.644 | 0 | 0 |
| Maturation of protein E | R-HSA-9683683 | 1.333452e-01 | 0.875 | 0 | 0 |
| Maturation of protein E | R-HSA-9694493 | 1.333452e-01 | 0.875 | 0 | 0 |
| VLDL assembly | R-HSA-8866423 | 1.487154e-01 | 0.828 | 0 | 0 |
| CHL1 interactions | R-HSA-447041 | 1.638140e-01 | 0.786 | 0 | 0 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | R-HSA-9013700 | 1.932153e-01 | 0.714 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 2.215862e-01 | 0.654 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 1.438126e-01 | 0.842 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 1.270205e-01 | 0.896 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 1.397008e-01 | 0.855 | 0 | 0 |
| Modulation by Mtb of host immune system | R-HSA-9637628 | 1.786457e-01 | 0.748 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 1.244335e-01 | 0.905 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 2.235022e-01 | 0.651 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 1.736556e-01 | 0.760 | 0 | 0 |
| Pexophagy | R-HSA-9664873 | 2.075273e-01 | 0.683 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 2.050233e-01 | 0.688 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 2.051986e-01 | 0.688 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 2.075273e-01 | 0.683 | 0 | 0 |
| Suppression of apoptosis | R-HSA-9635465 | 2.215862e-01 | 0.654 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 1.244335e-01 | 0.905 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 1.316009e-01 | 0.881 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 1.563820e-01 | 0.806 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 2.313397e-01 | 0.636 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 1.364012e-01 | 0.865 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 1.649447e-01 | 0.783 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 2.281733e-01 | 0.642 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 2.096101e-01 | 0.679 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 1.800176e-01 | 0.745 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 1.649447e-01 | 0.783 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 2.319069e-01 | 0.635 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 1.736430e-01 | 0.760 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 1.611272e-01 | 0.793 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 1.332434e-01 | 0.875 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 2.215862e-01 | 0.654 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 1.736430e-01 | 0.760 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 1.179769e-01 | 0.928 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 1.932153e-01 | 0.714 | 0 | 0 |
| POLB-Dependent Long Patch Base Excision Repair | R-HSA-110362 | 2.353966e-01 | 0.628 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 1.649447e-01 | 0.783 | 0 | 0 |
| Interleukin-23 signaling | R-HSA-9020933 | 1.786457e-01 | 0.748 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 1.185475e-01 | 0.926 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 1.928425e-01 | 0.715 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 2.004602e-01 | 0.698 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 1.906765e-01 | 0.720 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 1.649717e-01 | 0.783 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 1.416377e-01 | 0.849 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 1.356298e-01 | 0.868 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 1.356298e-01 | 0.868 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 1.959221e-01 | 0.708 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 1.992992e-01 | 0.700 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 2.004602e-01 | 0.698 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 1.272997e-01 | 0.895 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 2.384742e-01 | 0.623 | 0 | 0 |
| Amine ligand-binding receptors | R-HSA-375280 | 2.384742e-01 | 0.623 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 2.422930e-01 | 0.616 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 2.450508e-01 | 0.611 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 2.450508e-01 | 0.611 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 2.489628e-01 | 0.604 | 0 | 0 |
| Defective EXT2 causes exostoses 2 | R-HSA-3656237 | 2.489628e-01 | 0.604 | 0 | 0 |
| Defective EXT1 causes exostoses 1, TRPS2 and CHDS | R-HSA-3656253 | 2.489628e-01 | 0.604 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 2.489628e-01 | 0.604 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 2.489628e-01 | 0.604 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 2.489628e-01 | 0.604 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 2.489628e-01 | 0.604 | 0 | 0 |
| Reversal of alkylation damage by DNA dioxygenases | R-HSA-73943 | 2.489628e-01 | 0.604 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | R-HSA-2691232 | 2.489628e-01 | 0.604 | 0 | 0 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | R-HSA-2691230 | 2.489628e-01 | 0.604 | 0 | 0 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | R-HSA-975144 | 2.489628e-01 | 0.604 | 0 | 0 |
| IRAK1 recruits IKK complex | R-HSA-937039 | 2.489628e-01 | 0.604 | 0 | 0 |
| VLDLR internalisation and degradation | R-HSA-8866427 | 2.489628e-01 | 0.604 | 0 | 0 |
| p75NTR recruits signalling complexes | R-HSA-209543 | 2.489628e-01 | 0.604 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 2.489628e-01 | 0.604 | 0 | 0 |
| OAS antiviral response | R-HSA-8983711 | 2.489628e-01 | 0.604 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 2.516343e-01 | 0.599 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 2.516343e-01 | 0.599 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 2.516343e-01 | 0.599 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 2.581438e-01 | 0.588 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 2.613301e-01 | 0.583 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 2.621402e-01 | 0.581 | 0 | 0 |
| Membrane binding and targetting of GAG proteins | R-HSA-174490 | 2.622891e-01 | 0.581 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 2.622891e-01 | 0.581 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 2.622891e-01 | 0.581 | 0 | 0 |
| NFE2L2 regulating tumorigenic genes | R-HSA-9818030 | 2.622891e-01 | 0.581 | 0 | 0 |
| Interleukin-6 signaling | R-HSA-1059683 | 2.622891e-01 | 0.581 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 2.648129e-01 | 0.577 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 2.738913e-01 | 0.562 | 0 | 0 |
| ERBB2 Activates PTK6 Signaling | R-HSA-8847993 | 2.753798e-01 | 0.560 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | R-HSA-975163 | 2.753798e-01 | 0.560 | 0 | 0 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | R-HSA-174495 | 2.753798e-01 | 0.560 | 0 | 0 |
| NRIF signals cell death from the nucleus | R-HSA-205043 | 2.753798e-01 | 0.560 | 0 | 0 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | R-HSA-5684264 | 2.753798e-01 | 0.560 | 0 | 0 |
| CRMPs in Sema3A signaling | R-HSA-399956 | 2.753798e-01 | 0.560 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 2.753798e-01 | 0.560 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 2.753798e-01 | 0.560 | 0 | 0 |
| Respiratory syncytial virus genome transcription | R-HSA-9828642 | 2.753798e-01 | 0.560 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 2.757316e-01 | 0.560 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 2.805507e-01 | 0.552 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 2.805507e-01 | 0.552 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 2.882390e-01 | 0.540 | 0 | 0 |
| G beta:gamma signalling through BTK | R-HSA-8964315 | 2.882390e-01 | 0.540 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 2.882390e-01 | 0.540 | 0 | 0 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | R-HSA-937072 | 2.882390e-01 | 0.540 | 0 | 0 |
| Translesion synthesis by REV1 | R-HSA-110312 | 2.882390e-01 | 0.540 | 0 | 0 |
| DNA Damage Reversal | R-HSA-73942 | 2.882390e-01 | 0.540 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 2.882390e-01 | 0.540 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 2.882390e-01 | 0.540 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 2.882390e-01 | 0.540 | 0 | 0 |
| TICAM1, RIP1-mediated IKK complex recruitment | R-HSA-168927 | 2.882390e-01 | 0.540 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 2.882390e-01 | 0.540 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 2.882390e-01 | 0.540 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 2.882390e-01 | 0.540 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 2.902111e-01 | 0.537 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 2.911568e-01 | 0.536 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 2.911568e-01 | 0.536 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 2.911568e-01 | 0.536 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 2.977284e-01 | 0.526 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 2.998954e-01 | 0.523 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 2.998954e-01 | 0.523 | 0 | 0 |
| Translesion synthesis by POLI | R-HSA-5656121 | 3.008707e-01 | 0.522 | 0 | 0 |
| KSRP (KHSRP) binds and destabilizes mRNA | R-HSA-450604 | 3.008707e-01 | 0.522 | 0 | 0 |
| Regulation of NF-kappa B signaling | R-HSA-9758274 | 3.008707e-01 | 0.522 | 0 | 0 |
| Regulation of BACH1 activity | R-HSA-9708530 | 3.008707e-01 | 0.522 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 3.034027e-01 | 0.518 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 3.047443e-01 | 0.516 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 3.047443e-01 | 0.516 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 3.056176e-01 | 0.515 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 3.130551e-01 | 0.504 | 0 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 3.132791e-01 | 0.504 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 3.132791e-01 | 0.504 | 0 | 0 |
| Translesion synthesis by POLK | R-HSA-5655862 | 3.132791e-01 | 0.504 | 0 | 0 |
| Defective B3GALT6 causes EDSP2 and SEMDJL1 | R-HSA-4420332 | 3.132791e-01 | 0.504 | 0 | 0 |
| Defective B4GALT7 causes EDS, progeroid type | R-HSA-3560783 | 3.132791e-01 | 0.504 | 0 | 0 |
| Regulation of innate immune responses to cytosolic DNA | R-HSA-3134975 | 3.132791e-01 | 0.504 | 0 | 0 |
| STAT5 activation downstream of FLT3 ITD mutants | R-HSA-9702518 | 3.132791e-01 | 0.504 | 0 | 0 |
| TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling | R-HSA-975110 | 3.132791e-01 | 0.504 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 3.173800e-01 | 0.498 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 3.173800e-01 | 0.498 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 3.173800e-01 | 0.498 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 3.173800e-01 | 0.498 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 3.173800e-01 | 0.498 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 3.193082e-01 | 0.496 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 3.239039e-01 | 0.490 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 3.241659e-01 | 0.489 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 3.254679e-01 | 0.487 | 0 | 0 |
| Defective B3GAT3 causes JDSSDHD | R-HSA-3560801 | 3.254679e-01 | 0.487 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 3.254679e-01 | 0.487 | 0 | 0 |
| Regulation of FZD by ubiquitination | R-HSA-4641263 | 3.254679e-01 | 0.487 | 0 | 0 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | R-HSA-190840 | 3.254679e-01 | 0.487 | 0 | 0 |
| Glycogen storage diseases | R-HSA-3229121 | 3.254679e-01 | 0.487 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 3.290236e-01 | 0.483 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 3.369023e-01 | 0.472 | 0 | 0 |
| PCNA-Dependent Long Patch Base Excision Repair | R-HSA-5651801 | 3.374412e-01 | 0.472 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 3.374412e-01 | 0.472 | 0 | 0 |
| Mismatch Repair | R-HSA-5358508 | 3.374412e-01 | 0.472 | 0 | 0 |
| Synaptic adhesion-like molecules | R-HSA-8849932 | 3.374412e-01 | 0.472 | 0 | 0 |
| Transport of connexons to the plasma membrane | R-HSA-190872 | 3.374412e-01 | 0.472 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 3.374412e-01 | 0.472 | 0 | 0 |
| Biosynthesis of Lipoxins (LX) | R-HSA-2142700 | 3.374412e-01 | 0.472 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 3.374412e-01 | 0.472 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 3.387367e-01 | 0.470 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 3.433740e-01 | 0.464 | 0 | 0 |
| Metabolism of polyamines | R-HSA-351202 | 3.433740e-01 | 0.464 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 3.457598e-01 | 0.461 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 3.484412e-01 | 0.458 | 0 | 0 |
| Translesion Synthesis by POLH | R-HSA-110320 | 3.492026e-01 | 0.457 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 3.492026e-01 | 0.457 | 0 | 0 |
| IKK complex recruitment mediated by RIP1 | R-HSA-937041 | 3.492026e-01 | 0.457 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 3.492026e-01 | 0.457 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 3.497871e-01 | 0.456 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 3.498254e-01 | 0.456 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 3.498254e-01 | 0.456 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 3.498254e-01 | 0.456 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 3.547958e-01 | 0.450 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 3.562553e-01 | 0.448 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 3.581316e-01 | 0.446 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 3.581316e-01 | 0.446 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 3.581316e-01 | 0.446 | 0 | 0 |
| Formation of ATP by chemiosmotic coupling | R-HSA-163210 | 3.607560e-01 | 0.443 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 3.607560e-01 | 0.443 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 3.607560e-01 | 0.443 | 0 | 0 |
| Post-chaperonin tubulin folding pathway | R-HSA-389977 | 3.607560e-01 | 0.443 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 3.607560e-01 | 0.443 | 1 | 1 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 3.607560e-01 | 0.443 | 0 | 0 |
| BBSome-mediated cargo-targeting to cilium | R-HSA-5620922 | 3.607560e-01 | 0.443 | 0 | 0 |
| Signaling by NODAL | R-HSA-1181150 | 3.607560e-01 | 0.443 | 0 | 0 |
| Glycogen synthesis | R-HSA-3322077 | 3.607560e-01 | 0.443 | 0 | 0 |
| Common Pathway of Fibrin Clot Formation | R-HSA-140875 | 3.607560e-01 | 0.443 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 3.618274e-01 | 0.441 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 3.626624e-01 | 0.440 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 3.629697e-01 | 0.440 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 3.678022e-01 | 0.434 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 3.721050e-01 | 0.429 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 3.721050e-01 | 0.429 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 3.721050e-01 | 0.429 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 3.721050e-01 | 0.429 | 0 | 0 |
| Prevention of phagosomal-lysosomal fusion | R-HSA-9636383 | 3.721050e-01 | 0.429 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 3.721050e-01 | 0.429 | 0 | 0 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | R-HSA-2979096 | 3.721050e-01 | 0.429 | 0 | 0 |
| PD-L1(CD274) glycosylation and translocation to plasma membrane | R-HSA-9931295 | 3.721050e-01 | 0.429 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 3.726283e-01 | 0.429 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 3.726283e-01 | 0.429 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 3.726283e-01 | 0.429 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 3.822592e-01 | 0.418 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 3.832532e-01 | 0.417 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 3.832532e-01 | 0.417 | 0 | 0 |
| Attachment and Entry | R-HSA-9694614 | 3.832532e-01 | 0.417 | 0 | 0 |
| Assembly Of The HIV Virion | R-HSA-175474 | 3.832532e-01 | 0.417 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 3.832532e-01 | 0.417 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 3.832532e-01 | 0.417 | 0 | 0 |
| Ribavirin ADME | R-HSA-9755088 | 3.832532e-01 | 0.417 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 3.942041e-01 | 0.404 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 3.942041e-01 | 0.404 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 3.942041e-01 | 0.404 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 3.942041e-01 | 0.404 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 3.943152e-01 | 0.404 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 4.061824e-01 | 0.391 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 4.067780e-01 | 0.391 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 4.067780e-01 | 0.391 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 4.129632e-01 | 0.384 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 4.129632e-01 | 0.384 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 4.155280e-01 | 0.381 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 4.155280e-01 | 0.381 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 4.155280e-01 | 0.381 | 0 | 0 |
| Plasma lipoprotein assembly | R-HSA-8963898 | 4.155280e-01 | 0.381 | 0 | 0 |
| Mitochondrial RNA degradation | R-HSA-9836573 | 4.155280e-01 | 0.381 | 0 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 4.155280e-01 | 0.381 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 4.156778e-01 | 0.381 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 4.156778e-01 | 0.381 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 4.156778e-01 | 0.381 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 4.251244e-01 | 0.371 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 4.251244e-01 | 0.371 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 4.259078e-01 | 0.371 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 4.259078e-01 | 0.371 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 4.259078e-01 | 0.371 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 4.259078e-01 | 0.371 | 0 | 0 |
| MicroRNA (miRNA) biogenesis | R-HSA-203927 | 4.259078e-01 | 0.371 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 4.259078e-01 | 0.371 | 1 | 0 |
| Laminin interactions | R-HSA-3000157 | 4.259078e-01 | 0.371 | 0 | 0 |
| PIWI-interacting RNA (piRNA) biogenesis | R-HSA-5601884 | 4.259078e-01 | 0.371 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 4.345181e-01 | 0.362 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 4.345181e-01 | 0.362 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 4.352645e-01 | 0.361 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 4.361038e-01 | 0.360 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 4.361038e-01 | 0.360 | 0 | 0 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | R-HSA-110373 | 4.361038e-01 | 0.360 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 4.361038e-01 | 0.360 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 4.361038e-01 | 0.360 | 0 | 0 |
| Suppression of phagosomal maturation | R-HSA-9637687 | 4.361038e-01 | 0.360 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 4.373756e-01 | 0.359 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 4.391938e-01 | 0.357 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 4.391938e-01 | 0.357 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 4.417487e-01 | 0.355 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 4.438549e-01 | 0.353 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 4.461194e-01 | 0.351 | 0 | 0 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | R-HSA-8866652 | 4.461194e-01 | 0.351 | 0 | 0 |
| ER Quality Control Compartment (ERQC) | R-HSA-901032 | 4.461194e-01 | 0.351 | 0 | 0 |
| Insulin processing | R-HSA-264876 | 4.461194e-01 | 0.351 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 4.485009e-01 | 0.348 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 4.493428e-01 | 0.347 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 4.527973e-01 | 0.344 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 4.547349e-01 | 0.342 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 4.574235e-01 | 0.340 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 4.577457e-01 | 0.339 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 4.612283e-01 | 0.336 | 0 | 0 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | R-HSA-917729 | 4.656219e-01 | 0.332 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 4.656219e-01 | 0.332 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 4.656219e-01 | 0.332 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 4.656219e-01 | 0.332 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 4.656219e-01 | 0.332 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 4.714886e-01 | 0.327 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 4.727608e-01 | 0.325 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 4.729322e-01 | 0.325 | 0 | 0 |
| Thrombin signalling through proteinase activated receptors (PARs) | R-HSA-456926 | 4.751149e-01 | 0.323 | 0 | 0 |
| GABA synthesis, release, reuptake and degradation | R-HSA-888590 | 4.751149e-01 | 0.323 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 4.751149e-01 | 0.323 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 4.787267e-01 | 0.320 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 4.844399e-01 | 0.315 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 4.844399e-01 | 0.315 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 4.844399e-01 | 0.315 | 0 | 0 |
| Cargo concentration in the ER | R-HSA-5694530 | 4.844399e-01 | 0.315 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 4.850729e-01 | 0.314 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 4.901982e-01 | 0.310 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 4.935998e-01 | 0.307 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 4.935998e-01 | 0.307 | 0 | 0 |
| HS-GAG degradation | R-HSA-2024096 | 4.935998e-01 | 0.307 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 4.940361e-01 | 0.306 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 4.958744e-01 | 0.305 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 5.025975e-01 | 0.299 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 5.025975e-01 | 0.299 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 5.025975e-01 | 0.299 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 5.040495e-01 | 0.298 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 5.071058e-01 | 0.295 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 5.071058e-01 | 0.295 | 0 | 0 |
| Acyl chain remodelling of PC | R-HSA-1482788 | 5.114359e-01 | 0.291 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 5.160989e-01 | 0.287 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 5.181735e-01 | 0.286 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 5.184597e-01 | 0.285 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 5.201178e-01 | 0.284 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 5.201178e-01 | 0.284 | 0 | 0 |
| Glycosaminoglycan-protein linkage region biosynthesis | R-HSA-1971475 | 5.201178e-01 | 0.284 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 5.201178e-01 | 0.284 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 5.201178e-01 | 0.284 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 5.201178e-01 | 0.284 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 5.201178e-01 | 0.284 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 5.201178e-01 | 0.284 | 0 | 0 |
| Calnexin/calreticulin cycle | R-HSA-901042 | 5.201178e-01 | 0.284 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 5.201178e-01 | 0.284 | 0 | 0 |
| Hyaluronan metabolism | R-HSA-2142845 | 5.201178e-01 | 0.284 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 5.221710e-01 | 0.282 | 0 | 0 |
| Acyl chain remodelling of PE | R-HSA-1482839 | 5.286459e-01 | 0.277 | 0 | 0 |
| HS-GAG biosynthesis | R-HSA-2022928 | 5.370230e-01 | 0.270 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 5.370230e-01 | 0.270 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 5.370230e-01 | 0.270 | 0 | 0 |
| Formation of Fibrin Clot (Clotting Cascade) | R-HSA-140877 | 5.370230e-01 | 0.270 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 5.398089e-01 | 0.268 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 5.451121e-01 | 0.264 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 5.452517e-01 | 0.263 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 5.503728e-01 | 0.259 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 5.533346e-01 | 0.257 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 5.533346e-01 | 0.257 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 5.544738e-01 | 0.256 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 5.555906e-01 | 0.255 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 5.612744e-01 | 0.251 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 5.612744e-01 | 0.251 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 5.612744e-01 | 0.251 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 5.612744e-01 | 0.251 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 5.612744e-01 | 0.251 | 0 | 0 |
| Pentose phosphate pathway | R-HSA-71336 | 5.612744e-01 | 0.251 | 0 | 0 |
| RAS processing | R-HSA-9648002 | 5.612744e-01 | 0.251 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 5.612744e-01 | 0.251 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 5.627537e-01 | 0.250 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 5.690735e-01 | 0.245 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 5.690735e-01 | 0.245 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 5.690735e-01 | 0.245 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 5.690735e-01 | 0.245 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 5.690735e-01 | 0.245 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 5.690735e-01 | 0.245 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 5.690735e-01 | 0.245 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 5.690735e-01 | 0.245 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 5.690735e-01 | 0.245 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 5.709401e-01 | 0.243 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 5.767345e-01 | 0.239 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 5.767345e-01 | 0.239 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 5.767345e-01 | 0.239 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 5.792137e-01 | 0.237 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 5.810338e-01 | 0.236 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 5.810338e-01 | 0.236 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 5.810338e-01 | 0.236 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 5.859926e-01 | 0.232 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 5.909877e-01 | 0.228 | 0 | 0 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | R-HSA-381676 | 5.916516e-01 | 0.228 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 5.957800e-01 | 0.225 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 5.967063e-01 | 0.224 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 6.035922e-01 | 0.219 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 6.060447e-01 | 0.217 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 6.060447e-01 | 0.217 | 0 | 0 |
| Synthesis of Leukotrienes (LT) and Eoxins (EX) | R-HSA-2142691 | 6.060447e-01 | 0.217 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 6.065866e-01 | 0.217 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 6.130506e-01 | 0.213 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 6.130506e-01 | 0.213 | 0 | 0 |
| Diseases associated with glycosaminoglycan metabolism | R-HSA-3560782 | 6.130506e-01 | 0.213 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 6.130506e-01 | 0.213 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 6.166965e-01 | 0.210 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 6.180249e-01 | 0.209 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 6.194885e-01 | 0.208 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 6.199322e-01 | 0.208 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 6.199322e-01 | 0.208 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 6.199322e-01 | 0.208 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 6.199322e-01 | 0.208 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 6.264583e-01 | 0.203 | 0 | 0 |
| Carboxyterminal post-translational modifications of tubulin | R-HSA-8955332 | 6.266920e-01 | 0.203 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 6.266920e-01 | 0.203 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 6.270224e-01 | 0.203 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 6.286686e-01 | 0.202 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 6.331939e-01 | 0.198 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 6.333318e-01 | 0.198 | 0 | 0 |
| NGF-stimulated transcription | R-HSA-9031628 | 6.333318e-01 | 0.198 | 0 | 0 |
| Plasma lipoprotein remodeling | R-HSA-8963899 | 6.333318e-01 | 0.198 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 6.333318e-01 | 0.198 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 6.349428e-01 | 0.197 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 6.376761e-01 | 0.195 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 6.376761e-01 | 0.195 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 6.386096e-01 | 0.195 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 6.398540e-01 | 0.194 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 6.398540e-01 | 0.194 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 6.398540e-01 | 0.194 | 0 | 0 |
| Chemokine receptors bind chemokines | R-HSA-380108 | 6.398540e-01 | 0.194 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 6.462606e-01 | 0.190 | 0 | 0 |
| Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | R-HSA-2162123 | 6.462606e-01 | 0.190 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 6.551765e-01 | 0.184 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 6.587351e-01 | 0.181 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 6.587351e-01 | 0.181 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 6.615000e-01 | 0.179 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 6.648069e-01 | 0.177 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 6.648069e-01 | 0.177 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 6.678555e-01 | 0.175 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 6.766295e-01 | 0.170 | 0 | 0 |
| Paracetamol ADME | R-HSA-9753281 | 6.766295e-01 | 0.170 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 6.766295e-01 | 0.170 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 6.823840e-01 | 0.166 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 6.823840e-01 | 0.166 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 6.826800e-01 | 0.166 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 6.880364e-01 | 0.162 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 6.880364e-01 | 0.162 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 6.880364e-01 | 0.162 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 6.924665e-01 | 0.160 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 6.935887e-01 | 0.159 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 6.935887e-01 | 0.159 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 6.935887e-01 | 0.159 | 0 | 0 |
| Heparan sulfate/heparin (HS-GAG) metabolism | R-HSA-1638091 | 6.990424e-01 | 0.155 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 6.990424e-01 | 0.155 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 6.990424e-01 | 0.155 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 7.042717e-01 | 0.152 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 7.043994e-01 | 0.152 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 7.043994e-01 | 0.152 | 0 | 0 |
| Kinesins | R-HSA-983189 | 7.043994e-01 | 0.152 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 7.043994e-01 | 0.152 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 7.043994e-01 | 0.152 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 7.043994e-01 | 0.152 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 7.043994e-01 | 0.152 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 7.043994e-01 | 0.152 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 7.096613e-01 | 0.149 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 7.106701e-01 | 0.148 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 7.148300e-01 | 0.146 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 7.148300e-01 | 0.146 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 7.148300e-01 | 0.146 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 7.184946e-01 | 0.144 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 7.198186e-01 | 0.143 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 7.199069e-01 | 0.143 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 7.248937e-01 | 0.140 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 7.248937e-01 | 0.140 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 7.297921e-01 | 0.137 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 7.354814e-01 | 0.133 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 7.393296e-01 | 0.131 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 7.393296e-01 | 0.131 | 0 | 0 |
| Collagen biosynthesis and modifying enzymes | R-HSA-1650814 | 7.439718e-01 | 0.128 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 7.492279e-01 | 0.125 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 7.514501e-01 | 0.124 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 7.530104e-01 | 0.123 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 7.530104e-01 | 0.123 | 0 | 0 |
| Retinoid metabolism and transport | R-HSA-975634 | 7.574098e-01 | 0.121 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 7.574098e-01 | 0.121 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 7.574098e-01 | 0.121 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 7.617311e-01 | 0.118 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 7.617311e-01 | 0.118 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 7.659756e-01 | 0.116 | 0 | 0 |
| Diseases of carbohydrate metabolism | R-HSA-5663084 | 7.659756e-01 | 0.116 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 7.687115e-01 | 0.114 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 7.700511e-01 | 0.113 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 7.701448e-01 | 0.113 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 7.701448e-01 | 0.113 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 7.742400e-01 | 0.111 | 0 | 0 |
| Iron uptake and transport | R-HSA-917937 | 7.742400e-01 | 0.111 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 7.782625e-01 | 0.109 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 7.807197e-01 | 0.108 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 7.860944e-01 | 0.105 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 7.860944e-01 | 0.105 | 0 | 0 |
| Developmental Lineage of Pancreatic Acinar Cells | R-HSA-9925561 | 7.899063e-01 | 0.102 | 0 | 0 |
| Metabolism of fat-soluble vitamins | R-HSA-6806667 | 7.973284e-01 | 0.098 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 7.973284e-01 | 0.098 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 7.973284e-01 | 0.098 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 8.009408e-01 | 0.096 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 8.031088e-01 | 0.095 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 8.054416e-01 | 0.094 | 0 | 0 |
| Arachidonate metabolism | R-HSA-2142753 | 8.083803e-01 | 0.092 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 8.109062e-01 | 0.091 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 8.113976e-01 | 0.091 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 8.147601e-01 | 0.089 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 8.147601e-01 | 0.089 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 8.147601e-01 | 0.089 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 8.180628e-01 | 0.087 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 8.306973e-01 | 0.081 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 8.306973e-01 | 0.081 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 8.372809e-01 | 0.077 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 8.391980e-01 | 0.076 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 8.395958e-01 | 0.076 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 8.452677e-01 | 0.073 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 8.534028e-01 | 0.069 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 8.585699e-01 | 0.066 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 8.585699e-01 | 0.066 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 8.585881e-01 | 0.066 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 8.585881e-01 | 0.066 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 8.632013e-01 | 0.064 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 8.635905e-01 | 0.064 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 8.655216e-01 | 0.063 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 8.684166e-01 | 0.061 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 8.684166e-01 | 0.061 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 8.718328e-01 | 0.060 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 8.718645e-01 | 0.060 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 8.797503e-01 | 0.056 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 8.840585e-01 | 0.054 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 8.934784e-01 | 0.049 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 8.958951e-01 | 0.048 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 8.977549e-01 | 0.047 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 8.979678e-01 | 0.047 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 8.997147e-01 | 0.046 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 9.013758e-01 | 0.045 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 9.048689e-01 | 0.043 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 9.065690e-01 | 0.043 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 9.098787e-01 | 0.041 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 9.146256e-01 | 0.039 | 0 | 0 |
| Regulation of Complement cascade | R-HSA-977606 | 9.176509e-01 | 0.037 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 9.287207e-01 | 0.032 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 9.287207e-01 | 0.032 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 9.299957e-01 | 0.032 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 9.360381e-01 | 0.029 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 9.423534e-01 | 0.026 | 0 | 0 |
| Biosynthesis of specialized proresolving mediators (SPMs) | R-HSA-9018678 | 9.446431e-01 | 0.025 | 0 | 0 |
| Complement cascade | R-HSA-166658 | 9.466077e-01 | 0.024 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 9.485027e-01 | 0.023 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 9.485427e-01 | 0.023 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 9.512203e-01 | 0.022 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 9.537950e-01 | 0.021 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 9.539460e-01 | 0.020 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 9.546342e-01 | 0.020 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 9.554357e-01 | 0.020 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 9.570184e-01 | 0.019 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 9.592880e-01 | 0.018 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 9.666345e-01 | 0.015 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 9.703597e-01 | 0.013 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 9.741050e-01 | 0.011 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 9.770500e-01 | 0.010 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 9.771909e-01 | 0.010 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 9.816489e-01 | 0.008 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 9.853391e-01 | 0.006 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 9.854914e-01 | 0.006 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 9.923045e-01 | 0.003 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 9.962135e-01 | 0.002 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 9.962135e-01 | 0.002 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 9.972667e-01 | 0.001 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 9.975760e-01 | 0.001 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 9.994432e-01 | 0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 9.999995e-01 | 0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 9.999998e-01 | 0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 9.999999e-01 | 0.000 | 0 | 0 |